Pathology of multiple sclerosis explained

Multiple sclerosis (MS) can be pathologically defined as the presence of distributed glial scars (scleroses) in the central nervous system that must show dissemination in time (DIT) and in space (DIS) to be considered MS lesions.[1] [2]

The scars that give the name to the condition are produced by the astrocyte cells attempting to heal old lesions.[3] These glial scars are the remnants of previous demyelinating inflammatory lesions (encephalomyelitis disseminata) which are produced by the one or more unknown underlying processes that are characteristic of MS.

Apart from the disseminated lesions that define the condition, the CNS white matter normally shows other kinds of damage. At least five characteristics are present in CNS tissues of MS patients: Inflammation beyond classical white matter lesions (NAWM, NAGM), intrathecal Ig production with oligoclonal bands, an environment fostering immune cell persistence, Follicle-like aggregates in the meninges (B-cells mostly infected with EBV[4]) and a disruption of the blood–brain barrier even outside of active lesions.[5]

Confluent subpial cortical lesions are the most specific finding for MS, being exclusively present in MS patients.[6] Though this feature can only be detected during an autopsy[7] there are some subrogate markers under study[8] Damage in MS consists also in areas with hidden damage (normal appearing white and gray matters) and two kinds of cortical lesions: Neuronal loss and cortical demyelinating lesions. The neural loss is the result of neural degeneration from lesions located in the white matter areas and the cortical demyelinating lesions are related to meningeal inflammation.[9] [10]

The scars in the white matter are known to appear from confluence of smaller ones[11]

Currently the term "multiple sclerosis" is ambiguous and refers not only to the presence of the scars, but also to the unknown underlying condition that produces these scars. Besides clinical diagnosis uses also the term "multiple sclerosis" for speaking about the related clinical courses. Therefore, when referring to the presence of the scars is better to use the equivalent term astrocytic fibrillary gliosis.[9]

Lesions consistent with MS

A combination of histologic and/or immunohistochemical stains can be used to visualize post-mortem MS characteristic lesions and to diagnose post-mortem "inflammatory demyelinating lesions consistent with MS":[12]

These markers are specific for the different processes that drive the formation of plaques: inflammation, myelin breakdown, astrogliosis, oligodendrocyte injury, neurodegeneration, axonal loss and remyelination. MS lesions evolve differently during early versus chronic disease phases, and within each phase, different kind of activity appears.

The classification system for the lesions was updated in 2017. This system classifies MS lesions as active, mixed active/inactive, or inactive lesions based on the presence and distribution of macrophages/microglia. They locate the slowly expanding lesions inside the mixed subtype and provide a description of the different lesion types and required staining techniques.[13]

To consider some lesions as a case of MS, even under autopsy, they must be disseminated in time and space. Dissemination in time can be shown by the stage of the lesion evolution. If only a lesion is present it could be a case of solitary sclerosis.

MS is usually defined as the presence of disseminated lesions in space and time with no other explanation for them. Therefore, given the unspecificity of the lesions, several MS pathological underlying conditions have been found, which are now considered separate diseases.[14] There are at least three kind of lesions that were historically considered inside the MS spectrum and now are considered as separate entities:

Demyelination process

Lesions in MS are heterogeneous and there are four different patterns in which they start, probably due to different underlying pathogenesis. Nevertheless, it seems than the last stage of damage is similar for all of them. Traditionally it was thought that MS lesions were produced by CD4+ T-cells but after the discovery of anti-MOG and anti-NF demyelinating diseases, it has been noticed that most CD4+ cases are anti-MOG in reality, and now CD8+ cases are considered the real MS cases.[15]

In some cases (pattern II), a special subset of lymphocytes, called T helper cells or "CD4+ T-cells" play a key role in the development of the lesion in a way similar to the CD4+ attacks that appear in anti-MOG associated encephalomyelitis.[16] [17] [15]

In the standard cases, the trigger and the underlying condition of MS is a soluble factor produced by CD8+ T-cells (or maybe B-cells).[15] Also B Cells have been implicated in the pathogenesis of MS,[18] and some theoretical models link the presence of EBV-infected B-cells to the development of MS.

The first stage of a MS lesion is thought to be the development of an area called "normal appearing white matter" (NAWM).[19] In this area activated microglia appears, as shown by positron emission tomography. MS lesions appear in these areas as pre-active lesions without autoimmune infiltrates at this stage[20] They show microglia activation and degeneration of the neuron axons without T-cell infiltration. Both problems appear together though it is not known which one is first.[21]

T-cells attack is followed by leaks in the blood–brain barrier where T-cells infiltrate causing the known demyelination.[22]

HERVs and microglia

Human endogenous retroviruses (HERVs) have been reported in MS for several years. In fact, one of the families, Human Endogenous Retrovirus-W was first discovered while studying MS patients.

Recent research as of 2019 point to one of the HERV-W viruses (pHEV-W), and specifically one of the proteins of the viral capside that has been found to "activate microglia" in vitro. Activated microglia in turn produces demyelination.[23] Some interactions between the Epstein-Barr virus and the HERVs could be the trigger of the MS microglia reactions.[24] Supporting this study, a monoclonal antibody against the viral capside (Temelimab) has shown good results in trials in phase IIb.[25]

Last stage damage

Regardless of which kind of trigger initiates the damage, the axons themselves[26] and the oligodendrocytes.[27] are finally damaged by the T-cell attacks.[28] Often, the brain is able to compensate for some of this damage, due to an ability called neuroplasticity. MS symptoms develop as the cumulative result of multiple lesions in the brain and spinal cord. This is why symptoms can vary greatly between different individuals, depending on where their lesions occur.

Repair processes, called remyelination, also play an important role in MS. Remyelination is one of the reasons why, especially in early phases of the disease, symptoms tend to decrease or disappear temporarily. Nevertheless, nerve damage and irreversible loss of neurons occur early in MS.

The oligodendrocytes that originally formed a myelin sheath cannot completely rebuild a destroyed myelin sheath. However, the central nervous system can recruit oligodendrocyte stem cells capable of proliferation and migration and differentiation into mature myelinating oligodendrocytes. The newly formed myelin sheaths are thinner and often not as effective as the original ones. Repeated attacks lead to successively fewer effective remyelinations, until a scar-like plaque is built up around the damaged axons. These scars are the so-called "scleroses" that define the condition. They are named glial scars because they are produced by glial cells, mainly astrocytes, and their presence prevents remyelination. Therefore, there is research ongoing to prevent their formation.

Under laboratory conditions, stem cells are quite capable of proliferating and differentiating into remyelinating oligodendrocytes; it is therefore suspected that inflammatory conditions or axonal damage somehow inhibit stem cell proliferation and differentiation in affected areas[29]

Specific areas of damage

The unknown underlying condition produces inflammation, demyelination and atrophy in several areas. Some of the body tissues mentioned, like the retina, do not have myelin. In those cases, only inflammation and atrophy appears.

Brain lesions distribution

Main: Lesional demyelinations of the CNSMultiple sclerosis is considered a disease of the white matter because normally lesions appear in this area, but it is also possible to find some of them in the grey matter.[30]

Using high field MRI system, with several variants several areas show lesions, and can be spacially classified in infratentorial, callosal, juxtacortical, periventricular, and other white matter areas.[31] Other authors simplify this in three regions: intracortical, mixed gray-white matter, and juxtacortical.[32] Others classify them as hippocampal, cortical, and WM lesions,[33] and finally, others give seven areas: intracortical, mixed white matter-gray matter, juxtacortical, deep gray matter, periventricular white matter, deep white matter, and infratentorial lesions.[34] The distribution of the lesions could be linked to the clinical evolution[35]

Post-mortem autopsy reveal that gray matter demyelination occurs in the motor cortex, cingulate gyrus, cerebellum, thalamus and spinal cord.[36] Cortical lesions have been observed specially in people with SPMS but they also appear in RRMS and clinically isolated syndrome. They are more frequent in men than in women[37] and they can partly explain cognitive deficits.

Regarding two parameters of the cortical lesions (CLs), fractional anisotropy (FA) is lower and mean diffusivity (MD) is higher in patients than in controls.[38] The differences are larger in SPMS (secondary progressive multiple sclerosis) than in RRMS (relapsing-remitting multiple sclerosis) and most of them remain unchanged for short follow-up periods. They do not spread into the subcortical white matter and never show gadolinium enhancement. Over a one-year period, CLs can increase their number and size in a relevant proportion of MS patients, without spreading into the subcortical white matter or showing inflammatory features similar to those of white matter lesions.[39]

Due to the distribution of the lesions, since 1916 they are also known as Dawson's fingers.[40] They appear around the brain blood vessels.

Spinal cord damage

Cervical spinal cord has been found to be affected by MS even without attacks, and damage correlates with disability.[41] In RRMS, cervical spinal cord activity is enhanced, to compensate for the damage of other tissues.[42] It has been shown that Fractional anisotropy of cervical spinal cord is lower than normal, showing that there is damage hidden from normal MRI.[43]

Progressive tissue loss and injury occur in the cervical cord of MS patients. These two components of cord damage are not interrelated, suggesting that a multiparametric MRI approach is needed to get estimates of such a damage. MS cord pathology is independent of brain changes, develops at different rates according to disease phenotype, and is associated to medium-term disability accrual.[44]

Spinal cord presents grey matter lesions, that can be confirmed post-mortem and by high field MR imaging. Spinal cord grey matter lesions may be detected on MRI more readily than GM lesions in the brain, making the cord a promising site to study the grey matter demyelination.[45] Myelin Water Fraction (MWF) shows lesions under MRI[46]

Several CSF markers reveal intrathecal inflammation in progressive MS (SPMS and PPMS)[47]

Cerebellum and Thalamus

Cerebellar ataxia appears mainly in PPMS and it is related to the pathological changes in the cerebellum. Some special cells present only in the cerebellum, Purkinje cells, have been reported to be part of this problems. Increasing of neurofilament phosphorylation has been reported[48]

Cerebellum is specially affected in progressive variants. Grey matter damage in the cerebellum is linked to inflammation in the subarachnoid space[49] Though most of the cerebellum damage occurs in late stages, it can be seen that there are abnormalities since early disease stages[50] mostly of the "Normal Appearing" kind[51]

Thalamus degeneration in MS presents several features, such as trans-neuronal or Wallerian degeneration.[52]

Cortex

Around 26% of MS lesions appear inside or adjacent to the cortex.[53] It seems that in RRMS patients, both deep and cortical GM atrophy are associated with pathology in connected white matter.[54] Cortical lesions are inflammatory (immune mediated) and can present relapses[55]

Cortex lesions are disposed around the principal cortical veins and the majority enter the terrain of the white matter, and have been classified into seven types[53]

Some research groups have proposed that cortical lesions are the origin of the NAWM areas in the white matter[56] and 7 Tesla scanners seem to confirm this hypothesis, showing that cortical pathology starts in the pial surface (external layer of the brain), which is in contact with the CSF, and extends later into the brain inner layers.[57]

Lesions in the cortex have been classified by the area they affect into four groups: type I (leukocortical), type II (intracortical), type III (subpial), and type IV (subpial extending through the whole cortical width but not to subcortical WM). This classification is not related to the white matter lesions classification.[58] [59]

Normal appearing cortex

As with Normal appearing white matter (NAWM) and gray matter (NAGM), there is a Normal Appearing Cortex (NAC) in which no lesions have developed, but with abnormal microscopical properties. The NAC shows extensive RNA oxidation.[60]

Recently it has been found that Normal Appearing Cortex presents primary neurodegenerative damage in the dendritic spines of the neurons, with no demyelination nor autoimmune infiltrates. For some authors this constitutes a proof to state that MS is a primary neurodegenerative condition.[61]

Motor cortex

fibrinogen is deposited in MS motor cortex and associates with neurodegeneration.[62]

Olfactory bulb

The olfactory nerve, similar to the optic nerve, is part of the Central Nervous System. This nerve terminates in the olfactory bulb, which also belongs to the central nervous system. Both develop from the CNS embrion, and recently it has been shown, by autopsies, that they are affected by the same diseases than the rest of the CNS.[63] In particular, they are damaged during the multiple sclerosis course.

Related to this, the CSF of patients with disease activity show high levels of "Lateral Olfactory Tract Usher Substance" (LOTUS)[64]

Retina and optic nerve damage

The eye's retina in MS is also damaged. Given that retina cells have no myelin, damage must be different from the autoimmune attack of the brain. The underlying condition in the retina produces pure neurodegeneration.[65]

The retina and the optic nerve originate as outgrowths of the brain during embryonic development, so they are considered part of the central nervous system (CNS).[66] It is the only part of the CNS that can be imaged non-invasively in the living organism. The retina nerve fiber layer (RNFL) is thinner than normal in MS patients[67]

The procedure by which the MS underlying condition attacks the retina is currently unknown, but seems mediated by human leukocyte antigen-DR positive cells with the phenotype of microglia.[68]

MS patients show axonal loss in the retina and optic nerve, which can be measured by Optical coherence tomography[69] or by Scanning laser polarimetry.[70] This measure can be used to predict disease activity[71] and to establish a differential diagnosis from Neuromyelitis optica[72]

About antibodies in the retina, tissue-bound IgG was demonstrated on retinal ganglion cells in six of seven multiple sclerosis cases but not in controls.[73] Two eye problems, Uveitis and retinal phlebitis are manifestations of MS.[74]

Proposed procedures for the neurodegeneration are than Narrower arterioles and wider venules have been reported.[75] Also rigidity has been noticed[76]

Degenerative process in the optic nerve and retina

Human retina is devoid of myelin, but inflammation is prominent in MS even at late stages of disease, showing prominent gliosis and inflammation surrounding the vessels of the inner retina.[77]

Some results suggest the presence of trans-synaptic degeneration as a contributor to chronic axon damage in the optic nerve and retina[78] Nevertheless, the authors of the paper were unable to identify whether the degeneration condition spreads from the anterior part or from the rear.

The optic radiation (OR), which is a set of axons that lead to the visual cortex, is more similar to the rest of the brain because it contains myelin. It is also damaged. In this area NAWM areas (see below) appear. The optic radiation damage is composed by two factors: trans-synaptic degeneration, and wallerian degeneration[79]

Respect the theory about the role of the meninges in MS evolution, it is important to notice that the optic nerve in its intraorbital part has the tree meninges and it is tightly coupled with the pia mater.[80]

Neural and axonal damage

Two different mechanisms of axon destruction are acting in MS. First of all, there is a diffuse axon degeneration, probably related to the NAWM appearance. Later, there is a second axonal damage mechanism localized in old demyelinating lesions, probably produced by B-Cells. This second damage is related to the T1-Hypointense lesions (MRI black holes) which appear when a demyelinating lesion is not remyelinated.

The axons of the neurons are damaged probably by B-Cells,[28] though currently no relationship has been established with the relapses or the attacks.[26] It seems that this damage is a primary target of the immune system, i.e. not secondary damage after attacks against myelin,[81] though this has been disputed[82]

Proton magnetic resonance spectroscopy has shown that there is widespread neuronal loss even at the onset of MS, largely unrelated to inflammation.[83]

A relationship between neural damage and N-Acetyl-Aspartate concentration has been established, and this could lead to new methods for early MS diagnostic through magnetic resonance spectroscopy.[84]

Axonal degeneration at CNS can be estimated by N-acetylaspartate to creatine (NAA/Cr) ratio, both measured by with proton magnetic resonance spectroscopy.[85]

The meninges in multiple sclerosis

The meninges are three layers that protect the brain and the spinal cord. They are called (from the outside to the inside) the dura mater, the arachnoid mater and the pia mater. The cerebrospinal fluid flows between the second and the third one. A remarkable finding in MS is that some Follicle-like aggregates appear in the meninges (composed by B-cells mostly infected with EBV[4]). These aggregates grow during the disease process and is mostly found in secondary progressive patients.

Inflammation in the meninges has been found to be associated to gray mater (cortical) demyelination. Besides subpial demyelination suggest either a problem in the CSF or in the pia mater that should protect the cortex[86]

Whatever the underlying condition for MS is, some damage is triggered by a CSF unknown soluble factor, which is produced in meningeal areas and diffuses into the cortical parenchyma. It destroys myelin either directly or indirectly through microglia activation.[6]

The infiltration into meninges, which has been referred to as Tertiary Lymphoid Tissues (TLTs), prepares the infiltration into the CNS parenchyma causing demyelination in subpial and cortical areas. Animal models suggest that infiltrating Th17 cells remodel the meningeal stromal (non-immune) cells and initiate the formation of TLTs during EAE. The remodeled stromal cells retain and promote the production of Th17 and the accumulation of B cells. The collaboration between LTB on Th17 cells and LTBR (Lymphotoxin beta receptor) on meningeal radio-resistant cells is very crucial for the induction and progression of MS.[87]

Meningeal tertiary lymphoid-like structures

Follicle-like aggregates in the meninges are formed only in secondary progressive MS.[88] and correlate with the degree of subpial cortical demyelination and brain atrophy, suggesting that they might contribute to cortical pathology in SPMS[88]

These ectopic lymphoid follicles are composed mainly of EBV infected B-cells.[89]

Peripheral nervous system involvement

Though MS is defined as a CNS condition, some reports link problems in the peripheral nervous system with the presence of MS plaques in the CNS[90] Currently, a new disease entity, combined central and peripheral demyelination has been defined as the simultaneous demyelination of the periferal and central nervous systems.

Lesion structure and evolution

MS lesions mainly consist in demyelination and scarring in the fatty myelin sheaths around the axons of the brain and spinal cord.[91]

Lesions evolve from the Normal Appearing White Matter. In MTR-MRI, the apparent diffusion coefficient (ADCav) is a measure of water molecule motion. It can be seen that before the BBB breakdown, this coefficient increases until, at some point, the blood-brain barrier breaks down and immune cells enter the brain producing the lesion.[92]

According with the most recent (2009) research, an active lesion is composed of different layers:[93]

Some lesions named "slowly eroding lesions" or "slowly expanding" feature myelin phagocytosis at the lesion edge and evolve expanding across the white matter.[94]

Lesions under MRI

Most MS lesions are isointense to white matter (they appear bright) on T1-weighted MRI, but some are "hypointense" (lower intensity). These are called "black holes" (BH). They appear specially in the supratentorial region of the brain.

When BH's appear, around half of them revert in a month. This is considered a sign of remyelination. When they remain, this is regarded as a sign of permanent demyelination and axonal loss. This has been shown on post-mortem autopsies.[95]

Small lesions are invisible under MRI. Therefore, clinically assisted diagnostic criteria are still required for a more accurate MS diagnosis than MRI alone.[96]

The lesion evolution under MRI has been reported to begin as a pattern of central hyperintensity. This was seen in the majority of new lesions, both on proton density and contrast-enhanced T1-weighted images.[97] When gadolinium is used, the lesion expansion can be classified as nodular or ringlike.[98]

Whatever the demyelination process is, currently it is possible to detect lesions before demyelination, and they show clusters of activated microglia and leukocyte infiltration, together with oligodendrocytes abnormalities. Some research groups consider some areas of the NAWM with clusters of microglial nodules as "preactive MS lesions".[99] but their relevance is disputed.[100]

Lesion evolution can be followed via MRI[101]

Damage before BBB disruption

Special MRI methods

Main Magnetic resonance imaging

The classic MRI methods are named T1-relaxation and T2-relaxation. They create the images based in the "relaxation time", i.e., the time it takes for a molecule to realign its magnetic with its environment after an electromagnetic pulse has taken it out of the equilibrium.

A third type of MRI is based in the water diffusivity. It is called "Diffusion MRI" or "Diffusion Tensor MRI". and the images produced are normally named Diffusion Tensor Images (DTI). A modification of the image post-processing is to account for the water density in each area. These are called "Diffusion Weighted Images" (DWI) or Diffusion Tensor MRI, DT-MRI. The diffusion measures the water response and the tensor structure takes account of the orientation of the tissue fibers. It is important because NAWM and NAGM show abnormal DT-MRI[102]

A fourth important MRI technique is the Magnetization Transfer technique, MT-MRI. It measures differences in the Magnetization Transfer Ration (MTR). The idea is that the nucleus of any atom that has a net nuclear spin and that is bonded to a hydrogen atom could potentially be imaged via "heteronuclear magnetization transfer MRI". This would image the high-gyromagnetic-ratio hydrogen nucleus instead of the low-gyromagnetic-ratio nucleus that is bonded to the hydrogen atom.[103] In principle, hetereonuclear magnetization transfer MRI could be used to detect the presence or absence of specific chemical bonds.[104] [105] NAWM and Diffusely abnormal areas (DAWM) appear under MT-MRI.

Finally, the fifth more important MRI technique is the Proton Magnetic resonance spectroscopy. Based in the different response to the electromagnetic pulses that different substances present, an MRS scanner is able to identify chemical substances in the brain. This is important because N‐acetylaspartate is a marker of axonal damage that can be now identified in-vivo.[106]

Lesions under the special MRI methods

Normally two different kind of lesions appear on a normal MRI: T2-hypertense lesions and T1-hypointense. The first one are demyelinating lesions and appear brighter than the surroundings in T2-MRI.

The T1-hypointense are areas less dense than the surrounding NAW, and appear black on T1-MRI. They are mainly axonal degeneration areas. Because their black appearance they are sometimes known as black holes. They seem to appear as a sequel after a strong demyelinating lesion.

BBB disruption is normally shown using gadolinium. It is a contrast that cannot cross the BBB except when it is dysfunctional. Therefore, in active lesions with BBB implication the contrast enters the brain and appears in the MRI.

Before BBB disruption, some brain tissues which present normal aspect under T1 and T2 MRI (Normal appearing white matter, NAWM and normal appearing grey matter, NAGM), can show several abnormalities under special MRI technologies:

Magnetization transfer multi-echo T(2) relaxation. Subjects with Long-T(2) lesions had a significantly longer disease duration than subjects without this lesion subtype.[107] It has been found that grey matter injury correlates with disability[108] and that there is high oxidative stress in lesions, even in the old ones.[109]

Diffusion tensor MRI or Magnetic Transfer MRI are two options to enhance MRI-hidden abnormalities discovery. This is currently an active field of research with no definitive results, but it seems that these two technologies are complementary.[110]

Other methods of MRI allow us to get a better insight of the lesions structure. Recently MP-RAGE MRI has shown better results than PSIR and DIR for gray matter lesions.[111] Susceptibility weighted imaging (SWI-MRI) has shown iron (hemosiderin) deposition in lesions, and helps to detect otherwise invisible lesions.[112]

Abnormalities in the gray matter (Diffusion tensor MRI alterations) of the brain parenchyma are present early in the course of multiple sclerosis[113]

Normal appearing brain tissues

Using several texture analysis technologies, it is possible to classify white matter areas into three categories: normal, normal-appearing and lesions.[114] Currently, it is possible to detect lesions before they present demyelination, and they are called pre-active lesions.[115] A fourth area called DAWM (diffusely abnormal white matter) has been proposed[116] and can help to differentiate PPMS and SPMS.[117] Abundant extracellular myelin in the meninges of patients with multiple sclerosis has been found[118]

Brain tissues with MRI-hidden problems are usually named Normal Appearing. Exploring the normal-appearing corpus callosum has been found a possible primary hypoperfusion,[119] according with other findings in this same direction.[120] [121] [122] [123] [124] [125] Also iron (in hemosiderin deposits and as well as in ferritin-like structures inside the macrophage) accumulation has been reported[126] [127]

Several findings in these areas have been shown. Post-mortem studies over NAWM and NAGM areas (Normal appearing White and Gray Matters) show several biochemical alterations, like increased protein carbonylation and high levels of Glial fibrillary acidic protein (GFAP), which in NAGM areas comes together with higher than normal concentration of protein carbonyls, suggesting reduced levels of antioxidants and the presence of small lesions.[128] The amount of interneuronal Parvalbumin is lower than normal in brain's motor cortex areas,[129] and oxidative injury of oligodendrocytes and neurons could be associated with active demyelination and axonal injury.[130]

NAWM in MS has been reported to be similar to NAWM in leukoaraiosis,[131] though NAWM damage in MS is inflammatory and special microscopic techniques like CARS microscopy show that the CNS of MS patients may be globally altered, and both lesions and NAWM are just manifestations of another underlying problem.[132] The NAWM is specially abnormal close to the ventricles, which may indicate a pathogenic mechanism mediated via the CSF or ependyma.[133]

Non-lesional White Matter

Most of the brain in MS is unaffected. Though obviously normal white matter appears normal under MRI, so does the NAWM white matter described in the next section. To establish a difference, normal white matter is named Non-lesional white matter (NLWM)[134]

This normal white matter is reported to be around 56% of the total WM of the patients.[135]

Normal appearing White Matter

The white matter with hidden but MRI-visible damage is known as "Normal-appearing white matter" (NAWM)[136] and is where lesions appear.[22] The NAWM is considered a non-visible kind of lesion, produces disability and it is responsive to natalizumab

The pathology of the NAWM differs from areas near the lesions or near the cortex. Close to WM lesions, axonal pathology and microglial activation may explain subtle MRI changes. Distant from lesions, microglial activation associated with proximity to cortical lesions might underlie MRI abnormalities.[137]

The NAWM precedes the lesions. It has been shown that the apparent diffusion coefficient (ADC) precedes the development of new plaques. Later increases during BBB breakdown (gadolinium enhancement) and finally decays after the enhancement.[138]

BBB disruption takes place on NAWM areas.[139] This can be read in different ways. Maybe some hidden changes in White Matter structure trigger the BBB disruption, or maybe the same process that creates the NAWM areas disrupts the BBB after some time.

Pre-active lesions are lesions in an early stage of development. They resolve sometimes without further damage, and not always develop into demyelinating lesions. They present clusters of activated microglia in otherwise normal-appearing white matter.[115] [99]

Oligodendrocyte abnormalities appear to be crucially involved.[140] [141] The earliest change reported in the lesions examined is widespread oligodendrocyte apoptosis in which T cells, macrophages, activated microglia, reactive astrocytes, and neurons appear normal. This observation points to some change in the local environment (NAWM) to which oligodendrocytes are especially susceptible and which triggers a form of apoptosis.[142]

Water diffusivity is higher in all NAWM regions, deep gray matter regions, and some cortical gray matter region of MS patients than normal controls.[143]

Citrullination appears in SPMS.[144] It seems that a defect of sphingolipid metabolism modifies the properties of normal appearing white matter.[145] Related to these, peptidylarginine deiminase 2 is increased in patients with MS, and is related to arginine de-imination.[146]

NAWM shows a decreased perfusion which does not appear to be secondary to axonal loss.[123] The reduced perfusion of the NAWM in MS might be caused by a widespread astrocyte dysfunction, possibly related to a deficiency in astrocytic beta(2)-adrenergic receptors and a reduced formation of cAMP, resulting in a reduced uptake of K(+) at the nodes of Ranvier and a reduced release of K(+) in the perivascular spaces.[147] This would be consistent again with cases of Chronic cerebrospinal venous insufficiency.

White matter lesions appear in NAWM areas,[22] and their behavior can be predicted by MRI parameters as MTR (magnetization transfer ratio).[148] [149] This MTR parameter is related to axonal density.[150]

It also seems that myelin basic protein (MBP) from multiple sclerosis (MS) patients contains lower levels of phosphorylation at Thr97 than normal individuals.[151]

NAWM is the place where lesions appear and the process seems to be made by microglia, in absence of leukocyte infiltration, astrogliosis or demyelination. At the final stage of the process, these microglia develop into active demyelinating MS lesion[152]

In PPMS there is evidence that NAWM is affected by the same pathological processes that characterize WM lesions, namely inflammation, demyelination, axonal injury, macrophage infiltration and gliosis. Some evidence suggests that WM changes predict subsequent GM abnormalities, rather than the opposite. Anomalies in NAWM rather than lesions have a greater impact on later GM damage.[153]

Gray matter damage. Normal Appearing Gray Matter

Gray matter tissue damage dominates the pathological process as MS progresses, and underlies neurological disability. Imaging correlates of gray matter atrophy indicate that mechanisms differ in RRMS and SPMS.[154] Epstein-Barr virus could be involved,[155] but is not likely.[156] Involvement of the deep gray matter (DGM), suggested by magnetic resonance imaging, is confirmed, and most DGM lesions involve both GM and white matter. Inflammation in DGM lesions is intermediate between the destructive inflammation of white matter lesions and the minimal inflammation of cortical lesions.[157]

Iron depositions appear in deep gray matter by magnetic field correlation MRI[158] Differently from NAWM, NAGM areas are not related to the development of lesions[159]

Diffusely abnormal white matter

Other active area of study is the Diffusely abnormal white matter (DAWM). It seems to be a reduction of myelin phospholipids that correlates with a reduction of the myelin water fraction.[160] The DAWM consisted of extensive axonal loss, decreased myelin density, and chronic fibrillary gliosis, all of which were substantially abnormal compared with normal-appearing WM and significantly different from focal WM lesion pathology.[161] Changes in the vasculature take place not only in focal lesions but also in DAWM as detected by postmortem MRI[162]

Dirty appearing white matter

Dirty-appearing white matter (referred to as DAWM like the former case) is defined as a region with ill-defined borders of intermediatesignal intensity between that of normal-appearing white matter (NAWM) and that of plaque on T2-weighted and proton density imaging.[163] It is probably created by loss of myelin phospholipids, detected by the short T2 component, and axonal reduction.

Microglial nodules

Originally proposed as a biomarker,[164] the presence of these nodules has a possible pathogenetic significance. Though their role in the lesion evolution is still unclear, their presence in normal-appearing white matter have been suggested to be an early stage of lesion formation [165]

Heterogeneity of the disease

Multiple sclerosis has been reported to be heterogeneous in its behavior, in its underlying mechanisms, in its response to medication [166] and remarkably, also respect the response to the specific potassium channel autoantibody Kir4.1.[167]

For some authors, what we call MS in reality is a heterogeneous group of diseases[168] Some independent reports take also PPMS apart[169] Some others point a connection between some MS cases and peripheral neuropathies[170]

Some reports propose the existence of molecular biomarkers that determine the clinical course of the disease,[171] but the relationship to the pathological types has still not been established as of 2016.

Demyelination patterns

Four different damage patterns have been identified in patients' brain tissues. The original report suggests that there may be several types of MS with different immune causes, and that MS may be a family of several diseases. Though originally was required a biopsy to classify the lesions of a patient, since 2012 it is possible to classify them by a blood test[172] looking for antibodies against seven lipids, three of which are cholesterol derivatives.[173]

It is believed that they may correlate with differences in disease type and prognosis, and perhaps with different responses to treatment. In any case, understanding lesion patterns can provide information about differences in disease between individuals and enable doctors to make more accurate treatment decisions

Patterns I and II show the classical pathological features of MS lesions with microglia and macrophages, while patterns III and IV are considered atypical and could be separated from the MS spectrum at some point.[174] [175]

The four identified patterns are:[176]

Pattern I : The scar presents T-cells and macrophages around blood vessels, with preservation of oligodendrocytes, but no signs of complement system activation.[177]
Pattern II : The scar presents T-cells and macrophages around blood vessels, with preservation of oligodendrocytes, as before, but also signs of complement system activation can be found.[178] This pattern has been considered similar to damage seen in NMO, though AQP4 damage does not appear in pattern II MS lesions[179] Nevertheless, pattern II has been reported to respond to plasmapheresis,[180] which points to something pathogenic into the blood serum.

The complement system infiltration in these cases convert this pattern into a candidate for research into autoimmune connections like anti-Kir4.1,[181] anti-Anoctamin-2[182] or anti-MOG mediated MS[183] About the last possibility, research has found antiMOG antibodies in some pattern-II MS patients.[184]

Sometimes autoimmunity against the human CNS has been triggered by accident or medical mistake. The reactions have been diverse according to the sources of the disease but pathological confirmed MS (damage fulfills all pathological criteria of MS) is among them, and it shows pattern II[185]

Pattern II pathogenic T cells clonally expanded were found in the CN, specifically, CD4+ Th2 cells (secreting IL-4, L-5, and IL-13) have recently been described in pattern II MS, and their clones have been isolated as living cells[16] [17] [186] The functional characterization shows that T cells releasing Th2 cytokines and helping B cells dominate the T-cell infiltrate in pattern II brain lesions.[16]

Pattern III : The scars are diffuse with inflammation, distal oligodendrogliopathy and microglial activation. There is also loss of myelin-associated glycoprotein (MAG). The scars do not surround the blood vessels, and in fact, a rim of preserved myelin appears around the vessels. There is evidence of partial remyelinization and oligodendrocyte apoptosis. For some researchers this pattern is an early stage of the evolution of the others.[142] For others, it represents ischaemia-like injury with a remarkable availability of a specific biomarker in CSF[187] [188]

Some authors have stated that distal oligodendrogliopathy could come from a metabolic process.[189]

Pattern IV : The scar presents sharp borders and oligodendrocyte degeneration, with a rim of normal appearing white matter. There is a lack of oligodendrocytes in the center of the scar. There is no complement activation or MAG loss.

These differences are noticeable only in early lesions[190] and the heterogeneity was controversial during some time because some research groups thought that these four patterns could be consequence of the age of the lesions.[191] Nevertheless, after some debate among research groups, the four patterns model is accepted and the exceptional case found by Prineas has been classified as NMO[192] [193]

For some investigation teams this means that MS is a heterogeneous disease. The latter hypothesis is further corroborated by a recent study that demonstrated significant differences in routine cerebrospinal fluid findings between patients with pattern I lesions and patients with non-pattern I lesions, including a lack of CSF-restricted oligoclonal bands, in most pattern II and III patients.[194] Finally, some patients previously diagnosed with pattern II MS were later found to have in fact MOG-IgG-related encephalomyelitis, suggesting that both the current clinicoradiological diagnostic criteria for MS and the histopathological criteria for MS may be insufficiently specific.Currently antibodies to lipids and peptides in sera, detected by microarrays, can be used as markers of the pathological subtype given by brain biopsy.[195]

Other developments in this area is the finding that some lesions present mitochondrial defects that could distinguish types of lesions.[196]

MRI Phenotypes

Several studies trying to establish a relationship between the pathological findings and MRI findings have been performed.

For example, pulsed magnetization transfer imaging,[197] diffusion Tensor MRI,[198] and VCAM-1 enhanced MRI[199] have been reported to show the pathological differences of these patterns. Together with MRI, magnetic resonance spectroscopy allows to see the biochemical composition of the lesions, which shows at least two different patterns[200]

Currently as of 2014, the MRI studies have led to the proposal of four MRI phenotypes,[201] though both the classification and the relationship with the pathology remains controversial.

Other proposed correlations

Several correlations have been studied trying to establish a pathological classification:

Progressive MS

Primary progressive MS

It is currently discussed whether Primary Progressive MS (PPMS) is a different pathological entity or a different degree of the same pathology. No agreement has been established but there are some pathological features that are specific to PPMS. For example, meningeal inflammation is different respect standard cases of Recurrent-Recidivant MS (RRMS)[225] and sodium accumulation is higher.[226] Diffusely Abnormal White Matter (DAWM) is different than in RRMS/SPMS patients[227] and it has been shown that CSF from PPMS patients can transport the disease[169]

From a pathological point of view, PPMS characteristics are slow expansion of pre-existing white matter lesions, massive cortical demyelination, and extensive diffuse injury of the normal appearing white matter. As in relapsing MS also in progressive MS active tissue injury is invariably associated with inflammation, but inflammation seems to be trapped behind a closed blood brain barrier[228]

A specially remarkable difference between PPMS and SPMS are some follicle-like B-cells structures in the meninges of SPMS patients, that have never been reported in PPMS patients.[229] These follicles appear to be related to cortical demyelination in SPMS.

No disease modifying drug is approved for PPMS. Currently Natalizumab is being studied[230]

Secondary progressive MS

Secondary progressive MS shows follicle-like B-cells structures (a.k.a. Ectopic Follicle-Like Structures, EFS's, or Tertiary Lynphoid Tissues, TLT's) in the meninges that appear associated with underlying subpial cortical damage.[231] These follicles do not appear in Primary Progressive (PPMS)[232] nor in Remitant-Relapsing MS (RRMS).[233]

Pathology of early MS and silent MS

McDonald criteria rely in detecting the lesions disseminated in time and space that define MS by clinical observations. Therefore, normally they do not allow to establish a diagnosis for definite MS before two clinical attacks have appeared. This means that for clinical definite cases, MS condition has been present for a long time, complicating the study of the initial stages.[234] To study the initial stages of MS, some additional paraclinical tests must be used to prove the presence and dissemination of the lesions.[235]

Sometimes patients with their first isolated attack (Clinically Isolated syndrome, or CIS) but before the confirming second attack (Preclinical MS) can be accepted to study the initial MS pathology[236] but there is a study suggesting that any MS case begins as a silent pathology that can remain unnoticed even for five years.[237] Therefore, even the CIS can appear too late in MS evolution.

Cases of MS before the CIS are sometimes found during other neurological inspections and are referred to as subclinical MS.,[238] or sometimes Clinically silent MS.[239] The previous reference states that clinically silent MS plaques were located in the periventricular areas. This reference also reports an estimate of the prevalence of silent MS as high as about 25%. Oligodendrocytes evolution is similar to normal MS clinical courses[240]

Sometimes patients that undergo an MRI examination for an unrelated cause can show lesions in their brains. These cases of isolated MRI findings have been recently baptised as RIS (Radiologically Isolated Syndrome) and are the most common inspections in which suggestions of silent MS have appeared.[241]

In respect to the pathology of the RIS cases, we can point out that they show cortical lesions, mainly in patients with oligoclonal bands.[242] Macroscopic damage is similar to RRMS cases but milder.[243] Cervical cord lesions are an important predictor of progression[244] and the quotient N-acetylaspartate to creatine suggest axonal damage[245]

See also

External links

Notes and References

  1. Lublin FD . 2016 . Multiple Sclerosis and Other Inflammatory Diseases . Mount Sinai Expert Guides: Neurology . Sealfon SC, Motiwala R, Stacy CB . John Wiley & Sons, Ltd . Chichester, UK . 873–874. 10.1002/9781118621042.ch23 . 9781118621042 .
  2. Dutta R, Trapp BD . Pathology and definition of multiple sclerosis . Rev Prat. . June 30, 2006 . 56 . 12 . 1293–8. 16948216 .
  3. Brosnan CF, Raine CS . 2013 . The astrocyte in multiple sclerosis revisited . Glia . 61 . 4 . 453–465 . 10.1002/glia.22443 . 23322421 . 43783397 .
  4. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F . Sep 2008 . B cells and multiple sclerosis . Lancet Neurol . 7 . 9. 852–8 . 10.1016/S1474-4422(08)70192-3 . 18703007 . 7128448 .
  5. Meinl E, Krumbholz M, Derfuss T, Junker A, Hohlfeld R . Compartmentalization of inflammation in the CNS: A major mechanism driving progressive multiple sclerosis . J Neurol Sci . 274 . 1–2 . 42–4 . November 2008 . 18715571 . 10.1016/j.jns.2008.06.032. 34995402 .
  6. Lassmann H . 2014 . Multiple sclerosis: Lessons from molecular neuropathology . Experimental Neurology . 262 . 2–7 . 10.1016/j.expneurol.2013.12.003 . 24342027. 25337149 .
  7. Kutzelnigg A, etal . 2007 . Widespread Demyelination in the Cerebellar Cortex in Multiple Sclerosis . Brain Pathology . 17 . 1. 38–44 . 10.1111/j.1750-3639.2006.00041.x . 17493036. 8095596 . 38379112 . free .
  8. Absinta M, etal . Apr 2015 . Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis . Neurology . 85. 1. 18–28. 10.1212/WNL.0000000000001587 . 25888557 . 4501940.
  9. Bogdan F, Popescu GH, etal . Aug 2013 . ", Pathology of Multiple Sclerosis " Where Do We Stand? . Continuum . 19 . 4. 901–921 . 10.1212/01.CON.0000433291.23091.65 . 23917093 . 3915566.
  10. Haider L . 2016. The topograpy of demyelination and neurodegeneration in the multiple sclerosis . Brain . 139. 3. 807–15. 10.1093/brain/awv398. 4766379 . 26912645.
  11. 10.1093/brain/awp321 . Perivenous demyelination: Association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis . Brain . 133 . 2 . 333–48 . 2010 . Young . N. P . Weinshenker . B. G . Parisi . J. E . Scheithauer . B . Giannini . C . Roemer . S. F . Thomsen . K. M . Mandrekar . J. N . Erickson . B. J . Lucchinetti . C. F . 2822631 . 20129932.
  12. Popescu BF, Pirko I, Lucchinetti CF . Aug 2013 . Pathology of Multiple Sclerosis: Where Do We Stand? . Continuum . 19 . 4. 901–921 . 10.1212/01.CON.0000433291.23091.65 . 3915566 . 23917093.
  13. Kuhlmann T, Ludwin S, Prat A, etal . 2017 . An updated histological classification system for multiple sclerosis lesions . Acta Neuropathol . 133 . 1. 13–24 . 10.1007/s00401-016-1653-y . 27988845. 21115537 .
  14. Ayrignac, X., Rigau, V., Lhermitte, B. et al., Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions, J Neurol (2019). https://doi.org/10.1007/s00415-019-09328-7
  15. Lassmann H . 2019 . The changing concepts in the neuropathology of acquired demyelinating central nervous system disorders . Curr Opin Neurol . 32. 3. 313–319. 10.1097/WCO.0000000000000685 . 30893100 . 84841404 .
  16. Planas R, etal . 2015 . Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions . Annals of Clinical and Translational Neurology. 2. 9. 875–893. 10.1002/acn3.218 . 26401510 . 4574806 .
  17. Antel JP, Ludwin SK, Bar-Or A . 2015 . Sequencing the immunopathologic heterogeneity in multiple sclerosis . Annals of Clinical and Translational Neurology . 2. 9. 873–874. 10.1002/acn3.230 . 26401509 . 4574805.
  18. Hauser SL, Waubant E, Arnold DL . B-cell depletion with rituximab in relapsing-remitting multiple sclerosis . New England Journal of Medicine . 358 . 7 . 676–88 . February 2008 . 18272891 . 10.1056/NEJMoa0706383 . etal . free .
  19. 10.1111/ane.12845 . 29068494 . 136 . Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis . 2017 . Acta Neurologica Scandinavica . 15–17 . Zetterberg H. free .
  20. 10.1016/j.pneurobio.2015.02.003. 4578232 . 25802011 . 127–128 . The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis . 2015 . Prog. Neurobiol. . 1–22 . Mallucci G, Peruzzotti-Jametti L, Bernstock JD, Pluchino S.
  21. 10.1007/s00401-013-1082-0 . 23354834 . 3611040 . 125 . 4 . Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons . 2013 . Singh S, Metz I, Amor S, van der Valk P, Stadelmann C, Brück W . Acta Neuropathol . 595–608.
  22. Goodkin DE, Rooney WD, Sloan R . A serial study of new MS lesions and the white matter from which they arise . Neurology . 51 . 6 . 1689–97 . December 1998 . 9855524 . 10.1212/wnl.51.6.1689 . 21375563 . etal . 2015-02-11 . 2008-05-22 . https://web.archive.org/web/20080522131435/http://www.neurology.org/cgi/content/abstract/51/6/1689 . dead .
  23. Kremer et al., pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis, PNAS June 18, 2019, https://doi.org/10.1073/pnas.1901283116
  24. Robert P. Lisak, Human retrovirus pHEV-W envelope protein and the pathogenesis of multiple sclerosis, PNAS July 9, 2019 https://doi.org/10.1073/pnas.1909786116
  25. Hans-Peter Hartung et al, Efficacy and Safety of Temelimab, an Antibody Antagonist of the Human Endogenous Retrovirus Type-W env Protein, in Participants with Relapsing Remitting Multiple Sclerosis: A Double-Blind, Randomised, Placebo-Controlled Phase 2b Clinical Trial, The Lancet 17 May 2019 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3388820
  26. Pascual AM, Martínez-Bisbal MC, Boscá I . Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis . Neurology . 69 . 1 . 63–7 . 2007 . 17606882 . 10.1212/01.wnl.0000265054.08610.12 . 23230073 . etal .
  27. Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, Fan B, Ouamara N, Johnson TA, Rajasekharan S, Bar-Or A . Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro . J Neuroimmunol . May 2012 . 22458983 . 10.1016/j.jneuroim.2012.02.015 . 246 . 1–2 . 85–95 . 36221841 .
  28. http://www.physorg.com/news80230112.html Cause of nerve fiber damage in multiple sclerosis identified
  29. Wolswijk G . Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells . J Neurosci . 18 . 2 . 601–9 . 15 January 1998. 9425002 . 10.1523/JNEUROSCI.18-02-00601.1998. 6792542 .
  30. 15760868 . Cortical lesions in multiple sclerosis: Combined postmortem MR imaging and histopathology . 2005 . Geurts . J. J . AJNR. American Journal of Neuroradiology . 26 . 3 . 572–7 . Bö . L . Pouwels . P. J . Castelijns . J. A . Polman . C. H . Barkhof . F . 7976495.
  31. Wattjes MP, Harzheim M, Kuhl CK . Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis? . Am J Neuroradiol . 27 . 8 . 1794–8 . 1 September 2006. 16971638 . 8139807 . etal .
  32. Nelson F, Poonawalla AH, Hou P, Huang F, Wolinsky JS, Narayana PA . Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging . American Journal of Neuroradiology. 28 . 9 . 1645–9 . October 2007 . 17885241 . 10.3174/ajnr.A0645 . 8134176 . free .
  33. Roosendaal SD, Moraal B, Vrenken H . In vivo MR imaging of hippocampal lesions in multiple sclerosis . J Magn Reson Imaging . 27 . 4 . 726–31 . April 2008 . 18302199 . 10.1002/jmri.21294 . 46567107 . etal . free .
  34. Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA . Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging . Radiology . 236 . 1 . 254–60 . July 2005 . 15987979 . 10.1148/radiol.2361040450 .
  35. Sampat MP, Berger AM, Healy BC . Regional White Matter Atrophy–Based Classification of Multiple Sclerosis in Cross-Sectional and Longitudinal Data . American Journal of Neuroradiology. 30 . 9 . 1731–9 . October 2009 . 19696139 . 10.3174/ajnr.A1659 . 2821733 . etal .
  36. Gilmore CP, Donaldson I, Bö L, Owens T, Lowe JS, Evangelou N . Regional variations in the extent and pattern of grey matter demyelination in Multiple Sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord . Journal of Neurology, Neurosurgery & Psychiatry. October 2008 . 18829630 . 10.1136/jnnp.2008.148767 . 80 . 2 . 182–7. 7545552 . 1871/22404 . free .
  37. Calabrese M, De Stefano N, Atzori M . Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis . Arch Neurol . 64 . 10 . 1416–22 . 2007 . 17923625 . 10.1001/archneur.64.10.1416 . etal . free .
  38. Poonawalla AH, Hasan KM, Gupta RK . Diffusion-Tensor MR Imaging of Cortical Lesions in Multiple Sclerosis: Initial Findings . Radiology . 246. 3. 880–6. 2008 . 18195384 . 10.1148/radiol.2463070486 . etal .
  39. Calabrese M, Filippi M, Rovaris M, Mattisi I, Bernardi V, Atzori M, Favaretto A, Barachino L, Rinaldi L, Romualdi C, Perini P, Gallo P . Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study . NeuroImage. 42. 4. 1324–8. 2008 . 18652903 . 10.1016/j.neuroimage.2008.06.028 . 29732090 .
  40. http://radiopaedia.org/articles/dawson-fingers Dawson fingers, at Radiopedia
  41. Agosta F, Pagani E, Caputo D, Filippi M . Associations between cervical cord gray matter damage and disability in patients with multiple sclerosis . Arch Neurol . 64 . 9 . 1302–5 . 2007 . 17846269 . 10.1001/archneur.64.9.1302 .
  42. Agosta F, Valsasina P, Rocca MA, Caputo D, Sala S, Judica E, Stroman PW, Filippi M . Evidence for enhanced functional activity of cervical cord in relapsing multiple sclerosis . Magnetic Resonance in Medicine . 59. 5. 1035–42. 2008. 18429010 . 10.1002/mrm.21595 . free .
  43. 10.1590/S0004-282X2009000300004 . Cruz LC, Domingues RC, Gasparetto EL . Diffusion tensor imaging of the cervical spinal cord of patients with relapsing-remising multiple sclerosis: a study of 41 cases . Arq Neuropsiquiatr . 67 . 2B . 391–5 . June 2009 . 19623432 . free .
  44. Agosta F, Absinta M, Sormani MP . In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study . Brain . 130 . Pt 8 . 2211–9 . August 2007 . 17535835 . 10.1093/brain/awm110 . etal . free .
  45. Gilmore C, Geurts J, Evangelou N . Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging . Multiple Sclerosis . October 2008 . 18845658 . 10.1177/1352458508096876 . 15 . 2 . 180–8 \ . 35881980 . etal .
  46. 10.1177/1352458515624559 . 26819263 . High-resolution myelin water imaging in post-mortem multiple sclerosis spinal cord: A case report . Multiple Sclerosis Journal . 22 . 11 . 1485–1489 . 2016 . Laule . Cornelia . Yung . Andrew . Pavolva . Vlady . Bohnet . Barry . Kozlowski . Piotr . Hashimoto . Stanley A . Yip . Stephen . Li . David KB . Moore . GR Wayne . 32192027 .
  47. Mika Komori MD et al., Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis, Annals Neurolog. Volume78, Issue 1, July 2015, Pages 3-20, https://doi.org/10.1002/ana.24408
  48. 10.1111/bpa.12230 . 25411024 . 4780274 . Purkinje Cell Pathology and Loss in Multiple Sclerosis Cerebellum . Brain Pathology . 25 . 6 . 692–700 . 2015 . Redondo . Juliana . Kemp . Kevin . Hares . Kelly . Rice . Claire . Scolding . Neil . Wilkins . Alastair .
  49. 10.1111/nan.12199 . 25421634 . Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space . Neuropathology and Applied Neurobiology . 41 . 6 . 798–813 . 2015 . Howell . Owain W . Schulz-Trieglaff . Elena Katharina . Carassiti . Daniele . Gentleman . Steven M . Nicholas . Richard . Roncaroli . Federico . Reynolds . Richard . free .
  50. 10.1002/hbm.22698 . 25421928 . Multicontrastconnectometry: A new tool to assess cerebellum alterations in early relapsing-remitting multiple sclerosis . Human Brain Mapping . 36 . 4 . 1609–19 . 2015 . Romascano . David . Meskaldji . Djalel-Eddine . Bonnier . Guillaume . Simioni . Samanta . Rotzinger . David . Lin . Ying-Chia . Menegaz . Gloria . Roche . Alexis . Schluep . Myriam . Pasquier . Renaud Du . Richiardi . Jonas . Van De Ville . Dimitri . Daducci . Alessandro . Sumpf . Tilman . Fraham . Jens . Thiran . Jean-Philippe . Krueger . Gunnar . Granziera . Cristina . 6869568 .
  51. Deppe M . Apr 2015 . Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration . Mult Scler . 22. 1. 73–84. 10.1177/1352458515579439 . 25921041 . 27122132 . etal.
  52. Kipp M, Wagenknecht N, Beyer C, Samer S, Wuerfel J, Nikoubashman O . Nov 2014 . Thalamus pathology in multiple sclerosis: from biology to clinical application . Cell Mol Life Sci . 72. 6. 1127–47. 10.1007/s00018-014-1787-9 . 25417212 . 15376680 . 11113280 .
  53. Kidd D. . Barkhof F. . McConnell R. . Algra P. R. . Allen I. V. . Revesz T. . 1999 . Cortical lesions in multiple sclerosis . Brain . 122. 17–26. 10.1093/brain/122.1.17 . 10050891 . free .
  54. Steenwijk MD . 2015 . Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis . Hum Brain Mapp . 36. 5. 1796–1807. 10.1002/hbm.22738 . 25627545 . etal. 6869234 .
  55. Puthenparampil M . Mar 2015 . Cortical relapses in multiple sclerosis . Mult Scler . 22. 9. 1184–91 . 10.1177/1352458514564483 . 25791367 . 3806584 . etal.
  56. Mistry Niraj . Abdel-Fahim Rasha . Gowland Penny . A Corticocentric Model for Ms Pathogenesis . 2014 . Journal of Neurology, Neurosurgery & Psychiatry. 85 . 10. e4 . 10.1136/jnnp-2014-309236.135 . free .
  57. Mainero C . Feb 2015 . A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging . Brain . 138. Pt 4. 932–45. 10.1093/brain/awv011 . 25681411 . etal . 4677339.
  58. C. Mainero et al. Contribution of subpial pathology to cortical thinning in multiple sclerosis: a combined 7T - 3T MRI study, Proc. Intl. Soc. Mag. Reson. Med. 2010; 18
  59. Klaver R. . Apr 2015 . Neuronal and Axonal Loss in Normal-Appearing Gray Matter and Subpial Lesions in Multiple Sclerosis . J Neuropathol Exp Neurol . 74. 5. 453–8. 10.1097/NEN.0000000000000189 . 25853695 . etal. free .
  60. 10.1016/j.neuint.2015.12.002 . 26706235 . Evidence of extensive RNA oxidation in normal appearing cortex of multiple sclerosis brain . Neurochemistry International . 92 . 43–8 . 2016 . Kharel . Prakash . McDonough . Jennifer . Basu . Soumitra . 5531191 .
  61. Jürgens Tanja . Jafari Mehrnoosh . Kreutzfeldt Mario . Bahn Erik . Brück Wolfgang . Kerschensteiner Martin . Merkler Doron . 2016. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis . Brain. 139. Pt 1. 39–46. 10.1093/brain/awv353 . 26667278 . free .
  62. Yates R, Esiri M, Palace J, De Luca G . 2016 . Fibrinogen Deposition in the Multiple Sclerosis Motor Cortex . Neurology . 86 . 16. 369 . 10.1212/WNL.86.16_supplement.P1.369 .
  63. Gabriele . De Luca . Albert . Joseph . Jithin . George . Richard . Yates . Marie . Hamard . Margaret . Esiri . 2014 . Right Under Our Noses: Olfactory Pathology In Central Nervous System Demyelinating Diseases (P6.173) . Neurology . 82 . 10 . 6–173 .
  64. Takahashi . Dec 2014 . Association of Cerebrospinal Fluid Levels of Lateral Olfactory Tract Usher Substance (LOTUS) With Disease Activity in Multiple Sclerosis . JAMA Neurol . 72. 2. 176–9. 10.1001/jamaneurol.2014.3613 . 25437093 . etal.
  65. Frohman EM, Fujimoto JG, Frohman TC, Calabresi PA, Cutter G, Balcer LJ . Optical coherence tomography: a window into the mechanisms of multiple sclerosis . Nat Clin Pract Neurol . 4 . 12 . 664–75 . December 2008 . 19043423 . 2743162 . 10.1038/ncpneuro0950 .
  66. "eye, human."Encyclopædia Britannica. 2008. Encyclopædia Britannica 2006 Ultimate Reference Suite DVD
  67. 2013. Three-Dimensional Geometries Representing the Retinal Nerve Fiber Layer in Multiple Sclerosis, Optic Neuritis, and Healthy Eyes . Ophthal Res. 50. 1. 72–81. 10.1159/000350413 . 23774269 . Garcia-Martin E, Calvo B, Malvè M, Herrero R, Fuertes I, Ferreras A, Larrosa JM, Polo V, Pablo LE . 7218032 .
  68. Pulicken . 2007 . Optical coherence tomography and disease subtype in multiple sclerosis . Neurology . 69 . 22. 2085–2092 . 10.1093/brain/awq080 . etal . 20410146 . 2877904.
  69. Pueyo V, Martin J, Fernandez J, Almarcegui C, Ara J, Egea C, Pablo L, Honrubia F . Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis . Multiple Sclerosis . 14. 5. 609–14. 2008. 18424482 . 10.1177/1352458507087326 . 206696511 .
  70. Zaveri MS, Conger A, Salter A, Frohman TC, Galetta SL, Markowitz CE, Jacobs DA, Cutter GR, Ying GS, Maguire MG, Calabresi PA, Balcer LJ, Frohman EM . Retinal Imaging by Laser Polarimetry and Optical Coherence Tomography Evidence of Axonal Degeneration in Multiple Sclerosis . Archives of Neurology. 65. 7. 924–8. 2008. 18625859 . 10.1001/archneur.65.7.924 .
  71. Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, García-Layana A, Bejarano B, Villoslada P . Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS . Neurology . 68 . 18 . 1488–94 . May 2007 . 17470751 . 10.1212/01.wnl.0000260612.51849.ed . 13229292 .
  72. Naismith RT, Tutlam NT, Xu J . Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis . Neurology . 72 . 12 . 1077–82 . March 2009 . 19307541 . 10.1212/01.wnl.0000345042.53843.d5 . 2677471 . etal .
  73. Lucarelli MJ, Pepose JS, Arnold AC, Foos RY . Immunopathologic features of retinal lesions in multiple sclerosis . Ophthalmology . 98 . 11 . 1652–6 . November 1991 . 1724792 . 10.1016/s0161-6420(91)32080-3 .
  74. Kerrison JB, Flynn T, Green WR . Retinal pathologic changes in multiple sclerosis . Retina . 14 . 5 . 445–51 . 1994 . 7899721 . 10.1097/00006982-199414050-00010 . 7520310 .
  75. Gugleta K, Kochkorov A, Kavroulaki D . Retinal vessels in patients with multiple sclerosis: baseline diameter and response to flicker light stimulation . Klin Monatsbl Augenheilkd . 226 . 4 . 272–5 . April 2009 . 19384781 . 10.1055/s-0028-1109289 . 260197522 . etal .
  76. Kochkorov A, Gugleta K, Kavroulaki D . Rigidity of retinal vessels in patients with multiple sclerosis . Klin Monatsbl Augenheilkd . 226 . 4 . 276–9 . April 2009 . 19384782 . 10.1055/s-0028-1109291 . 6316227 . etal .
  77. 10.1093/brain/awq080 . 20410146 . 2877904 . Ocular pathology in multiple sclerosis: Retinal atrophy and inflammation irrespective of disease duration . Brain . 133 . 6 . 1591–601 . 2010 . Green . A. J . McQuaid . S . Hauser . S. L . Allen . I. V . Lyness . R .
  78. Gabilondo IM, Lapiscina EH, Heras E, Fraga PE, Llufriu S, Ortiz S, Villoslada P . 2014 . Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis . Annals of Neurology . 75 . 1. 98–107 . 10.1002/ana.24030. 24114885 . 1022517 .
  79. Maria . 2013 . Wallerian and trans-synaptic degeneration contribute to optic radiation damage in multiple sclerosis: a diffusion tensor MRI study . Mult Scler . 19 . 12. 1610–1617 . 10.1177/1352458513485146 . 23572238 . 24883445 . etal.
  80. Book: 10.1007/978-3-319-20970-8_2 . Anatomy of the Retina and the Optic Nerve . Optical Coherence Tomography in Multiple Sclerosis . 3–19 . 2016 . Evangelou . Nikos . Alrawashdeh . Omar S. M . 978-3-319-20969-2 .
  81. Huizinga R, Gerritsen W, Heijmans N, Amor S . Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments . Neurobiol Dis . September 2008 . 18804534 . 10.1016/j.nbd.2008.08.009 . 32 . 3 . 461–70 . 24878463 .
  82. Sobottka B, Harrer MD, Ziegler U . Collateral Bystander Damage by Myelin-Directed CD8+ T Cells Causes Axonal Loss . Am J Pathol . 175 . 3 . 1160–6 . September 2009 . 19700745 . 10.2353/ajpath.2009.090340 . 2731134 . etal .
  83. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, Martinelli V, Grossman R, Scotti G, Comi G, Falini A . Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis . Brain . 126 . Pt 2 . 433–7 . 2003 . 12538409 . 10.1093/brain/awg038 . free .
  84. http://www1.uni-bonn.de/pressDB/jsp/pressemitteilungsdetails.jsp?detailjahr=2007&detail=365 Neuer Diagnose-Ansatz zur Früherkennung von MS
  85. Mostert JP, Blaauw Y, Koch MW, Kuiper AJ, Hoogduin JM, De Keyser J . Reproducibility over a 1-month period of 1H-MR spectroscopic imaging NAA/Cr ratios in clinically stable multiple sclerosis patients . Eur Radiol . 18 . 1736–40 . 2008 . 18389250 . 10.1007/s00330-008-0925-x . 8 . 2469275 .
  86. Cortical Lesions in Multiple Sclerosis, Inflammation versus Neurodegeneration, Hans Lassmann, Brain. 2012;135(10):2904-2905. http://www.medscape.com/viewarticle/773247
  87. Liu LP . 2016 . Meningeal inflammation and multiple sclerosis. + Neuroimmunology and Neuroinflammation. 3 . 6. 145–6 . 10.20517/2347-8659.2016.22 . free .
  88. Oki S . Novel mechanisms of chronic inflammation in secondary progressive multiple sclerosis . Neuroimmunology . 9 . S1 . 13–19. March 2018 . 10.1111/cen3.12437 . free.
  89. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F . Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain . Journal of Experimental Medicine. 204 . 12 . 2899–2912 . Nov 2007 . 10.1084/jem.20071030 . free. 2118531 . 17984305.
  90. Poser Charles M . 1987. The peripheral nervous system in multiple sclerosis: A review and pathogenetic hypothesis . Journal of the Neurological Sciences. 79. 1–2. 83–90. 10.1016/0022-510X(87)90262-0 . 3302114. 35473342.
  91. Compston A, Coles A. Multiple sclerosis. Lancet. 372. 9648. 1502–17. October 2008. 18970977. 10.1016/S0140-6736(08)61620-7. 195686659.
  92. Werring D. J. . 2000 . The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosisA serial diffusion MRI study . Brain . 123. 8. 1667–76. 10.1093/brain/123.8.1667 . 10908196.
  93. 20035511 . vanc . Henderson . AP. 10.1002/ana.21800 . Barnett . MH . Parratt . JD . Prineas . JW . Multiple sclerosis: distribution of inflammatory cells in newly forming lesions . Annals of Neurology . 66 . 6 . December 2009 . 739–53. 12351557 .
  94. Sethi V, etal . 2016 . Slowly eroding lesions in multiple sclerosis . Mult Scler . 23. 3. 464–472 . 10.1177/1352458516655403 . 27339071 . 5182188 .
  95. van Walderveen M A; Kamphorst W; Scheltens P; van Waesberghe J H; Ravid R; Valk J; Polman C H; Barkhof F, Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. http://www.uptodate.com/online/content/abstract.do?topicKey=demyelin/4438&refNum=38
  96. 2156195 . 109 . 1–2 . Identification of two types of excitatory monosynaptic inputs in frog spinal motoneurones . February 1990 . Antonov SM, Kalinina NI, Kurchavyj GG, Magazanik LG, Shupliakov OV, Vesselkin NP . 82–7 . Neuroscience Letters . 10.1016/0304-3940(90)90541-G . 5772535 .
  97. Guttmann Charles R. G. . Ahn Sungkee S. . Hsu Liangge . Kikinis Ron . Jolesz Ferenc A. . 1995 . The Evolution of Multiple Sclerosis Lesions on Serial MR . Am J Neuroradiol . 16 . 7. 1481–1491 . 7484637 . 8338072 .
  98. Gaitán María I . July 2011 . Evolution of the Blood-Brain Barrier in Newly Forming Multiple Sclerosis Lesions . Ann Neurol . 70 . 1. 22–29 . 10.1002/ana.22472. etal. 3143223 . 21710622.
  99. Bsibsi M, Holtman IR, Gerritsen WH, Eggen BJ, Boddeke E, van der Valk P, van Noort JM, Amor S . Sep 2013 . Alpha-B-Crystallin Induces an Immune-Regulatory and Antiviral Microglial Response in Preactive Multiple Sclerosis Lesions . J Neuropathol Exp Neurol . 72. 10. 970–9. 10.1097/NEN.0b013e3182a776bf . 24042199 . free .
  100. 10.1002/glia.23090 . 27778395 . Complement C3 on microglial clusters in multiple sclerosis occur in chronic but not acute disease: Implication for disease pathogenesis . Glia . 65 . 2 . 264–277 . 2017 . Michailidou . Iliana . Naessens . Daphne M. P . Hametner . Simon . Guldenaar . Willemijn . Kooi . Evert-Jan . Geurts . Jeroen J. G . Baas . Frank . Lassmann . Hans . Ramaglia . Valeria . 5215693.
  101. Laura E. . 2015. Jonkman et al. Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study . Journal of Neurology . 262 . 4. 1074–1080 . 10.1007/s00415-015-7689-4 . etal. 4412507 . 25761376.
  102. 16775258 . Multiple sclerosis: The role of MR imaging . 2006 . Ge . Y . American Journal of Neuroradiology . 27 . 6 . 1165–76 . 8133908.
  103. Hurd RE, John BK . Gradient-enhanced proton-detected heteronuclear multiple-quantum coherence spectroscopy . Journal of Magnetic Resonance, Series A . 91 . 3 . 648–653 . February 1991 . 10.1016/0022-2364(91)90395-a . 1991JMagR..91..648H .
  104. Brown RA, Venters RA, Tang PP, Spicer LD . A test for scalar coupling between heteronuclei using gradient-enhanced proton-detected HMQC spectroscopy . Journal of Magnetic Resonance, Series A . 113 . 1 . 117–119 . March 1995 . 10.1006/jmra.1995.1064 . 1995JMagR.113..117B .
  105. Miller AF, Egan LA, Townsend CA . Measurement of the degree of isotopic enrichment of different positions in an antibiotic peptide by NMR . Journal of Magnetic Resonance . 125 . 1 . 120–131 . March 1997 . 10.1006/jmre.1997.1107. 9245367 . 1997JMagR.125..120M .
  106. 10.1093/brain/awg038 . Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis . Brain . 126 . 2 . 433–7 . 2003 . Filippi . M . 12538409. free .
  107. Laule C, Vavasour IM, Kolind SH . Long T(2) water in multiple sclerosis: What else can we learn from multi-echo T(2) relaxation? . J Neurol . 254 . 11 . 1579–87 . 2007 . 17762945 . 10.1007/s00415-007-0595-7 . 3149294 . etal .
  108. Zhang Y, Zabad R, Wei X, Metz LM, Hill MD, Mitchell JR . Deep grey matter 'black T2' on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis . Multiple Sclerosis. 13. 7. 880–3. 2007 . 17468444 . 10.1177/1352458507076411 . 12699795 .
  109. Holley JE, Newcombe J, Winyard PG, Gutowski NJ . Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes . Multiple Sclerosis. 13. 8. 955–61. 2007 . 17623739 . 10.1177/1352458507078064 . 19626529 .
  110. Otaduy MC, Callegaro D, Bacheschi LA, Leite CC . Correlation of magnetization transfer and diffusion magnetic resonance imaging in multiple sclerosis . Multiple Sclerosis . 12 . 6 . 754–9 . December 2006 . 17263003 . 10.1177/1352458506070824 . 43121559 .
  111. Nelson F, Poonawalla A, Hou P, Wolinsky J, Narayana P . 3D MPRAGE Improves Classification of Cortical Lesions in Multiple Sclerosis . Multiple Sclerosis . 14 . 9 . 1214–9 . November 2008 . 18952832 . 10.1177/1352458508094644 . 2650249 .
  112. Haacke EM, Makki M, Ge Y . Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging . J Magn Reson Imaging . 29 . 3 . 537–44 . March 2009 . 19243035 . 2650739 . 10.1002/jmri.21676 . etal .
  113. 10.1016/j.jns.2013.12.031 . 24423584 . Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome . Journal of the Neurological Sciences . 338 . 1–2 . 128–34 . 2014 . Cappellani . Roberto . Bergsland . Niels . Weinstock-Guttman . Bianca . Kennedy . Cheryl . Carl . Ellen . Ramasamy . Deepa P . Hagemeier . Jesper . Dwyer . Michael G . Patti . Francesco . Zivadinov . Robert . 12889417 .
  114. Zhang J, Tong L, Wang L, Li N . Texture analysis of multiple sclerosis: a comparative study . Magnetic Resonance Imaging. 26. 8. 1160–6. 2008. 18513908 . 10.1016/j.mri.2008.01.016 .
  115. van der Valk P, Amor S . Preactive lesions in multiple sclerosis . Current Opinion in Neurology . 22 . 3 . 207–13 . June 2009 . 19417567 . 10.1097/WCO.0b013e32832b4c76 . 46351467 .
  116. Seewann A, Vrenken H, van der Valk P . Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis . Arch Neurol . 66 . 5 . 601–9 . May 2009 . 19433660 . 10.1001/archneurol.2009.57 . etal . free .
  117. 19850760 . vanc . Vrenken . H. 10.3174/ajnr.A1839 . Seewann . A . Knol . DL . Polman . CH . Barkhof . F . Geurts . JJ . Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types . American Journal of Neuroradiology. 31 . 3 . March 2010 . 541–8. 7963986 . free .
  118. Kooi EJ, van Horssen J, Witte ME . Abundant extracellular myelin in the meninges of patients with multiple sclerosis . Neuropathol Appl Neurobiol . 35 . 3 . 283–95 . June 2009 . 19473295 . 10.1111/j.1365-2990.2008.00986.x . etal . free .
  119. Saindane AM, Law M, Ge Y, Johnson G, Babb JS, Grossman RI . 2007 . Correlation of Diffusion Tensor and Dynamic Perfusion MR Imaging Metrics in Normal-Appearing Corpus Callosum: Support for Primary Hypoperfusion in Multiple Sclerosis . American Journal of Neuroradiology . 28 . 4. 767–772 . 17416836 . 7977353 .
  120. Inglese Matilde . Adhya Sumita . Johnson Glyn . Babb James S . Miles Laura . Jaggi Hina . Herbert Joseph . Grossman Robert . 2008. Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis . Journal of Cerebral Blood Flow & Metabolism. 28. 1. 164–171. 10.1038/sj.jcbfm.9600504 . 2596621 . 17473851.
  121. Adhya Sumita . Johnson Glyn . Herbert Joseph . Jaggi Hina . Babb James S. . Grossman Robert I. . Inglese Matilde . 2006. Pattern of Hemodynamic Impairment in Multiple Sclerosis: Dynamic Susceptibility Contrast Perfusion MR Imaging at 3.0 T . NeuroImage. 33. 4. 1029–1035. 10.1016/j.neuroimage.2006.08.008 . 16996280 . 1752216.
  122. Varga AW, Johnson G, Babb JS, Herbert J, Grossman RI, Inglese M . White Matter Hemodynamic Abnormalities precede Sub-cortical Gray Matter Changes in Multiple Sclerosis . J Neurol Sci . 282 . 1–2 . 28–33 . July 2009 . 19181347 . 10.1016/j.jns.2008.12.036 . 2737614 . Inglese .
  123. 18594554 . vanc . De Keyser . J. 10.1038/jcbfm.2008.72 . Steen . C . Mostert . JP . Koch . MW . Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance . Journal of Cerebral Blood Flow and Metabolism . 28 . 10 . October 2008 . 1645–51.
  124. Inglese Matilde . Adhya Sumita . Johnson Glyn . Babb James S . Miles Laura . Jaggi Hina . Herbert Joseph . Grossman Robert I . 2008. Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis . Journal of Cerebral Blood Flow & Metabolism . 28. 1 . 164–171. 10.1038/sj.jcbfm.9600504 . 17473851 . 2596621.
  125. 15163806 . vanc . Law . M. 10.1148/radiol.2313030996 . Saindane . AM . Ge . Y . Babb . JS . Johnson . G . Mannon . LJ . Herbert . J . Grossman . RI . Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter . Radiology . 231 . 3 . June 2004 . 645–52.
  126. Adams . CW . Perivascular iron deposition and other vascular damage in multiple sclerosis . 3346691 . vanc . Journal of Neurology, Neurosurgery & Psychiatry. 51 . 2 . February 1988 . 260–5 . 1031540 . 10.1136/jnnp.51.2.260.
  127. Singh . AV . Zamboni . P . Anomalous venous blood flow and iron deposition in multiple sclerosis . 19724286 . vanc . Journal of Cerebral Blood Flow and Metabolism . 10.1038/jcbfm.2009.180 . 29 . 12 . December 2009 . 1867–78.
  128. Bizzozero OA, DeJesus G, Callahan K, Pastuszyn A . Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis . Journal of Neuroscience Research. 81. 5. 687–95. 2005. 16007681 . 10.1002/jnr.20587 . 45254727 .
  129. Clements RJ, McDonough J, Freeman EJ . Distribution of parvalbumin and calretinin immunoreactive interneurons in motor cortex from multiple sclerosis post-mortem tissue . Experimental Brain Research . 187. 3. 459–65. 2008. 18297277 . 10.1007/s00221-008-1317-9 . 18256420 .
  130. Haider Lukas . 2011. Oxidative damage in multiple sclerosis lesions . Brain . 134. 7. 1914–1924. 10.1093/brain/awr128 . etal . 21653539 . 3122372.
  131. Beggs Clive B . 2013 . Venous hemodynamics in neurological disorders: an analytical review with hydrodynamic analysis . BMC Medicine . 11 . 1. 142 . 10.1186/1741-7015-11-142. 23724917 . 3668302 . free .
  132. Book: 10.1117/12.2076654 . 2015SPIE.9305E..04P . Quantitative biochemical investigation of various neuropathologies using high-resolution spectral CARS microscopy . Optical Techniques in Neurosurgery, Neurophotonics, and Optogenetics II . 9305 . 930504 . 2015 . Poon . Kelvin W . Brideau . Craig . Schenk . Geert J . Klaver . Roel . Klauser . Antoine M . Kawasoe . Jean H . Geurts . Jeroen J . Stys . Peter K . Optical Techniques in Neurosurgery . 123016410 . Hirschberg . Henry . Madsen . Steen J . Jansen . E. Duco . Luo . Qingming . Mohanty . Samarendra K . Thakor . Nitish V .
  133. Chard Declan . 2015 . Association of Multiple Sclerosis Normal Appearing White Matter Abnormality with Periventricular Location and Secondary Progression . Neurology . 84 . 14 Suppl P6 . 126 . 10.1212/WNL.84.14_supplement.P6.126 . etal.
  134. Petzold A, Tozer DJ, Schmierer K . Dec 2011 . Axonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter . Exp Neurol . 232 . 2. 234–9 . 10.1016/j.expneurol.2011.09.011 . 21958956 . 3277890 .
  135. Barbosa S . 1994 . Magnetic resonance relaxation time mapping in multiple sclerosis: Normal appearing white matter and the "invisible" lesion load . Magnetic Resonance Imaging . 12 . 1. 33–42 . 10.1016/0730-725x(94)92350-7. 8295506 .
  136. Mangia S, Carpenter AF, Tyan AE, Eberly LE, Garwood M, Michaeli S . Lynn Eberly . Dec 2013 . Magnetization transfer and adiabatic T1ρ MRI reveal abnormalities in normal-appearing white matter of subjects with multiple sclerosis . Mult Scler . 20. 8. 1066–1073. 10.1177/1352458513515084 . 24336350 . 4205209 .
  137. Moll N. M. . Rietsch A. M. . Thomas S. . Ransohoff A. J. . Lee J.-C. . Fox R. . Chang A. . Ransohoff R. M. . Fisher E. . 2011 . Multiple sclerosis normal-appearing white matter: Pathology–imaging correlations . Ann Neurol . 70 . 5. 764–773 . 10.1002/ana.22521 . 3241216 . 22162059.
  138. Werring DJ, Brassat D, Droogan AG, Clark CA, Symms MR, Barker GJ, MacManus DG, Thompson AJ, Miller DH., The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study, NMR Research Unit, Queen Square, London, UK.
  139. Werring DJ, Brassat D, Droogan AG . The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study . Brain . 123 . 1667–76 . August 2000 . 10908196 . 10.1093/brain/123.8.1667. 8 . etal .
  140. Pathological abnormalities in the normal-appearing white matter in multiple sclerosis . 2001 . Neurol Sci . 11603615 . 22 . 2 . 141–4 . 10.1007/s100720170012 . McQuaid . S . Mirakhur . M . Nevin . G. Allen . 26091720 . 1 .
  141. Thomas Zeis . Ursula Graumann . Richard Reynolds . . Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection . 18056737 . Brain . 10.1093/brain/awm291 . 4 . Jan 2008 . 131 . 288–303. free .
  142. Barnett . MH . Prineas . JW . Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion . 15048884 . vanc . Annals of Neurology . 10.1002/ana.20016 . 55 . 4 . April 2004 . 458–68 . 5659495 . 2015-02-11 . https://web.archive.org/web/20131029184151/http://www.direct-ms.org/pdf/ImmunologyMS/Prineas%20new%20lesion.pdf . 2013-10-29 . dead .
  143. Phuttharak W, Galassi W, Laopaiboon V, Laopaiboon M, Hesselink JR . Abnormal diffusivity of normal appearing brain tissue in multiple sclerosis: a diffusion-weighted MR imaging study . J Med Assoc Thai . 90 . 12 . 2689–94 . 2007 . 18386722 .
  144. Nicholas AP, Sambandam T, Echols JD, Tourtellotte WW . Increased citrullinated glial fibrillary acidic protein in secondary progressive multiple sclerosis . The Journal of Comparative Neurology. 473. 1. 128–36. 2004. 15067723 . 10.1002/cne.20102 . 25651610 .
  145. Wheeler D, Bandaru VV, Calabresi PA, Nath A, Haughey NJ . A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis . Brain . 131 . Pt 11 . 3092–102 . November 2008 . 18772223 . 2577809 . 10.1093/brain/awn190 .
  146. Too Much Of A Charge-Switching Enzyme Causes Symptoms Of Multiple Sclerosis And Related Disorders In Mouse Models http://www.medicalnewstoday.com/articles/128393.php
  147. De Keyser J, Steen C, Mostert JP, Koch MW . Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance . Journal of Cerebral Blood Flow and Metabolism . 28. 10. 1645–51. 2008 . 18594554 . 10.1038/jcbfm.2008.72.
  148. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G . Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis . Annals of Neurology . 43 . 6 . 809–14 . June 1998 . 9629851 . 10.1002/ana.410430616 . 8504513 .
  149. Cercignani M, Iannucci G, Rocca MA, Comi G, Horsfield MA, Filippi M . Pathologic damage in MS assessed by diffusion-weighted and magnetization transfer MRI . Neurology . 54 . 5 . 1139–44 . March 2000 . 10720288 . 10.1212/wnl.54.5.1139. 23277778 .
  150. van Waesberghe JH, Kamphorst W, De Groot CJ . Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability . Annals of Neurology . 46 . 5 . 747–54 . November 1999 . 10553992 . 10.1002/1531-8249(199911)46:5<747::AID-ANA10>3.0.CO;2-4 . 38718037 . etal .
  151. Tait AR, Straus SK . Phosphorylation of U24 from Human Herpes Virus type 6 (HHV-6) and its potential role in mimicking myelin basic protein (MBP) in multiple sclerosis . FEBS Letters . 582 . 18 . 2685–8 . August 2008 . 18616943 . 10.1016/j.febslet.2008.06.050 . 2810681 . 2008FEBSL.582.2685T .
  152. Singh S, Metz I, Amor S, van der Valk P, Stadelmann C, Brück W . 2013 . Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons . Acta Neuropathologica . 125 . 4. 595–608 . 10.1007/s00401-013-1082-0. 23354834 . 3611040 .
  153. M. Margoni et al. Axonal water fraction as marker of white matter injury in primary‐progressive multiple sclerosis: a longitudinal study, European Journal of Neurology, February 2019, https://doi.org/10.1111/ene.13937
  154. Fisher E, Lee JC, Nakamura K, Rudick RA . Gray matter atrophy in multiple sclerosis: a longitudinal study . Annals of Neurology . 64 . 3 . 255–65 . September 2008 . 18661561 . 10.1002/ana.21436 . 16060268 .
  155. Zivadinov R, Zorzon M, Weinstock-Guttman B . Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis . Journal of Neurology, Neurosurgery & Psychiatry. 80 . 6 . 620–5 . June 2009 . 19168469 . 10.1136/jnnp.2008.154906 . 22515412 . etal .
  156. Willis SN, Stadelmann C, Rodig SJ . Epstein–Barr virus infection is not a characteristic feature of multiple sclerosis brain . Brain . 132. Pt 12. 3318–28. July 2009 . 19638446 . 10.1093/brain/awp200 . 2792367 . etal .
  157. Vercellino M, Masera S, Lorenzatti M . Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter . J Neuropathol Exp Neurol . 68 . 5 . 489–502 . May 2009 . 19525897 . 10.1097/NEN.0b013e3181a19a5a . etal . free .
  158. Ge Y, Jensen JH, Lu H . Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging . American Journal of Neuroradiology. 28 . 9 . 1639–44 . October 2007 . 17893225 . 10.3174/ajnr.A0646 . 8134218 . etal . free .
  159. Capellani Roberto . 2014 . Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome . Journal of the Neurological Sciences . 338 . 1–2. 128–134 . 10.1016/j.jns.2013.12.031 . etal . 24423584. 12889417 .
  160. 20965961 . vanc . Laule . C. 10.1177/1352458510384008 . Vavasour . IM . Leung . E . Li . DK . Kozlowski . P . Traboulsee . AL . Oger . J . MacKay . AL . Moore . GW . Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology . Multiple Sclerosis . October 2010 . 17 . 2 . 144–50 . 8522348 .
  161. 19433660 . 10.1001/archneurol.2009.57 . 66 . 5 . Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis . May 2009 . Seewann A, Vrenken H, van der Valk P . Arch Neurol . 601–9 . etal . free .
  162. 16039866 . 10.1016/j.nbd.2005.06.012 . 20 . 3 . Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis . December 2005 . Vos CM, Geurts JJ, Montagne L . Neurobiol Dis . 953–60 . 38550150 . etal .
  163. Moore G. R. W. . Laule C. . MacKay A. . Leung E. . Li D. K. B. . Zhao G. . Traboulsee A. L. . Paty D. W. . 2012 . Dirty-appearing white matter in multiple sclerosis . Journal of Neurology . 255 . 11. 1802–1811 . 10.1007/s00415-008-0002-z . 18821049 . 25266169 .
  164. Barnett MH, Parratt JD, Cho ES, Prineas JW . Jan 2009 . Immunoglobulins and complement in postmortem multiple sclerosis tissue . Ann Neurol . 65 . 1. 32–46 . 10.1002/ana.21524 . 19194879 . 41600459 .
  165. Singh S, Metz I, Amor S, van der Valk P, Stadelmann C, Brück W . Apr 2013 . Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons . Acta Neuropathol . 125 . 4. 595–608 . 10.1007/s00401-013-1082-0 . 23354834 . 3611040 .
  166. Leussink VI, Lehmann HC, Meyer Zu Hörste G, Hartung HP, Stüve O, Kieseier BC . Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab : Evidence for disease heterogeneity . Journal of Neurology . 255 . 9 . 1436–8 . September 2008 . 18685916 . 10.1007/s00415-008-0956-x . 38328163 .
  167. Srivastava R, etal . 2012 . Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis . New England Journal of Medicine . 367 . 2. 115–123 . 10.1056/NEJMoa1110740 . 22784115 . 5131800.
  168. 10.4199/C00116ED1V01Y201408ISP055 . Multiple Sclerosis: An Overview of Clinical Features, Pathophysiology, Neuroimaging, and Treatment Options . Colloquium Series on Integrated Systems Physiology: From Molecule to Function . 6 . 4 . 1–117 . 2014 . Minagar . Alireza .
  169. Cristofanilli M, Rosenthal H, Cymring B, Gratch D, Pagano B, Xie B, Sadiq SA . 2014 . Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice . Experimental Neurology . 261 . 620–632 . 10.1016/j.expneurol.2014.07.020 . 25111532 . 21263405 .
  170. Narupat Suanprasert el al. Polyneuropathies And Chronic Inflammatory Demyelinating Polyradiculoneuropathy In Multiple Sclerosis, Neurology April 6, 2015 vol. 84 no. 14 Supplement S42.001
  171. Enayetallah A, Hosur R, Ransohoff R, Goyal J . 2016 . Multiple Sclerosis Clinical Characteristics in Molecularly-Defined Patient Populations . Neurology . 86 . 16. S37.008 . 10.1212/WNL.86.16_supplement.S37.008 .
  172. Francisco . Quintana . Roya . Rahbari . Sandra . Magalhaes . Melissa . McGowan . Trina . Johnson . Sathyanath . Rajasekharan . Howard . Weiner . Brenda . Banwell . Amit . Bar-Or . 2012 . Specific Serum Antibody Patterns Detected with Antigen Arrays Are Associated to the Development of MS in Pediatric Patients (S60.006) . Neurology . 78 . 1 . S60–006 . 10.1212/WNL.78.1_MeetingAbstracts.S60.006 .
  173. 10.7224/1537-2073-14.S5.1 . 24453725 . 3882979 . Harnessing the Clinical Value of Biomarkers in Multiple Sclerosis . International Journal of MS Care . 14 . 1 . 1–20 . 2012 . Theuring . A .
  174. Lucchinetti. Claudia. Bruck. Wolfgang. Parisi. Joseph. Scheithauer. Bernd. Rodriguez. Moses. Lassmann. Hans. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of Neurology. June 2000. 47. 6. 707–17. 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q . 10852536. 14630021 .
  175. Rayan Bou Fakhredin, Charbel Saade, Racha Kerek, Lara El‐Jamal, Samia J Khoury, Fadi El‐Merhi, Imaging in multiple sclerosis: A new spin on lesions, 27 July 2016, doi: https://doi.org/10.1111/1754-9485.12498
  176. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H . Jul 1996 . Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis . Brain Pathol . 6 . 3. 259–74 . 8864283 . 10.1111/j.1750-3639.1996.tb00854.x . 7161824.
  177. Web site: Part 1B Pathology: Lecture 11 - The Complement System . 2006-05-10 . Nick . Holmes . 15 November 2001 . dead . https://web.archive.org/web/20060109221235/http://immserv1.path.cam.ac.uk/~immuno/part1/lec10/lec10_97.html . 9 January 2006 .
  178. Brain. 122. 12. 2279–2295. December 1999. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions - A study of 113 cases . Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H . 10.1093/brain/122.12.2279. 10581222. free.
  179. 19822791 . 10.1001/archneurol.2009.199 . 66 . 10 . Humoral pattern II multiple sclerosis pathology not associated with neuromyelitis Optica IgG . 2767176 . October 2009 . Kale N, Pittock SJ, Lennon VA . Arch Neurol . 1298–9 . etal .
  180. Wilner AN, Goodman A . Some MS patients have "Dramatic" responses to Plasma Exchange . Neurology Reviews . 8 . 3 . March 2000 . https://web.archive.org/web/20010223022848/http://www.neurologyreviews.com/mar00/nr_mar00_MSpatients.html . 2001-02-23.
  181. 10.1056/NEJMoa1110740 . 22784115 . 5131800 . Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis . New England Journal of Medicine . 367 . 2 . 115–23 . 2012 . Srivastava . Rajneesh . Aslam . Muhammad . Kalluri . Sudhakar Reddy . Schirmer . Lucas . Buck . Dorothea . Tackenberg . Björn . Rothhammer . Veit . Chan . Andrew . Gold . Ralf . Berthele . Achim . Bennett . Jeffrey L . Korn . Thomas . Hemmer . Bernhard .
  182. 10.1073/pnas.1518553113 . 26862169 . 4776531 . Anoctamin 2 identified as an autoimmune target in multiple sclerosis . Proceedings of the National Academy of Sciences . 113 . 8 . 2188–93 . 2016 . Ayoglu . Burcu . Mitsios . Nicholas . Kockum . Ingrid . Khademi . Mohsen . Zandian . Arash . Sjöberg . Ronald . Forsström . Björn . Bredenberg . Johan . Lima Bomfim . Izaura . Holmgren . Erik . Grönlund . Hans . Guerreiro-Cacais . André Ortlieb . Abdelmagid . Nada . Uhlén . Mathias . Waterboer . Tim . Alfredsson . Lars . Mulder . Jan . Schwenk . Jochen M . Olsson . Tomas . Nilsson . Peter . 2016PNAS..113.2188A . free .
  183. Spadaro M, etal . 2015 . Histopathology and clinical course of MOG-antibody-associated encephalomyelitis . Annals of Clinical and Translational Neurology . 2 . 3. 295–301 . 10.1002/acn3.164 . 25815356 . 4369279.
  184. Jarius S, Metz I, König FB, Ruprecht K, Reindl M, Paul F, Brück W, Wildemann B . 11 Feb 2016 . Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case . Mult Scler . 22 . 12 . 1541–1549 . 10.1177/1352458515622986 . 26869529 . 1387384 .
  185. 10.1186/s40478-015-0260-9 . Autoimmune encephalitis in humans: How closely does it reflect multiple sclerosis? . Acta Neuropathologica Communications . 3 . 2015 . Höftberger . Romana . Leisser . Marianne . Bauer . Jan . Lassmann . Hans . 26637427 . 4670499 . 80 . free .
  186. Martin R, Sospedra M, Rosito M, Engelhardt B . 2016 . Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis . Eur. J. Immunol. . 46 . 9. 2078–2090 . 10.1002/eji.201646485 . 27467894 . 27116660 .
  187. 10.1093/brain/awg127 . 12764056 . A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions . Brain . 126 . 6 . 1347–1357 . 2003 . Lassmann . Hans . Reindl . Markus . Rauschka . Helmut . Berger . Johannes . Aboul-Enein . Fahmy . Berger . Thomas . Zurbriggen . Andreas . Lutterotti . Andreas . Brück . Wolfgang . Weber . Jörg R . Ullrich . Robert . Schmidbauer . Manfred . Jellinger . Kurt . Vandevelde . Marc . free .
  188. 10.1093/brain/awm236 . Lesion genesis in a subset of patients with multiple sclerosis: A role for innate immunity? . Brain . 130 . 11 . 2800–2815 . 2007 . Marik . C . Felts . P. A . Bauer . J . Lassmann . H . Smith . K. J . 17956913 . 2981817 .
  189. Qiao Ling . Cui . Malena . Rone . Damla . Khan . Melissa . Bedard . Guillermina . Almazan . Samuel . Ludwin . Timophy . Kennedy . Jack . Antel . 2016 . Oligodendrogliopathy in Multiple Sclerosis: Relation to Low Glycolytic Metabolic Rate of Oligodendrocytes (I10.004) . Neurology . 86 . 16 . I10–004 .
  190. Breij EC, Brink BP, Veerhuis R . Homogeneity of active demyelinating lesions in established multiple sclerosis . Annals of Neurology . 63 . 1 . 16–25 . 2008 . 18232012 . 10.1002/ana.21311 . 205340842 . etal .
  191. Barnett MH, Prineas JW . Relapsing and Remitting Multiple Sclerosis: Pathology of the Newly Forming Lesion . Annals of Neurology . 55 . 1 . 458–468 . 2004 . 15048884 . 10.1002/ana.20016 . 5659495 . 2015-02-11 . 2016-03-04 . https://web.archive.org/web/20160304002500/http://www.cpnhelp.org/files/Ref1_Annals04.pdf . dead .
  192. Brück W, Popescu B, Lucchinetti CF, Markovic-Plese S, Gold R, Thal DR, Metz I . Sep 2012 . Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate . Ann Neurol . 72 . 3. 385–94 . 10.1002/ana.23621 . 23034911. 1662420 .
  193. Arnold P, Mojumder D, Detoledo J, Lucius R, Wilms H . Feb 2014 . Pathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathways . Clin Pharmacol . 6 . 35–42 . 10.2147/CPAA.S35033 . 24591852 . 3938468 . free .
  194. Jarius S, König FB, Metz I, Ruprecht K, Paul F, Brück W, Wildemann B . 29 Aug 2017 . Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis . J Neuroinflammation . 14 . 1 . 171 . 10.1186/s12974-017-0929-z . 28851393 . 5576197 . free .
  195. Quintana FJ, Farez MF, Viglietta V, Antonio HI, Yifat M, Guillermo I, Miguel L, Alexandre SB, Samia JK, Claudia FL, Irun RC, Howard LW . Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis . Proc Natl Acad Sci USA . 105 . 48 . 18889–94 . December 2008 . 19028871 . 2596207 . 10.1073/pnas.0806310105 . 1 . 2008PNAS..10518889Q . free .
  196. Mahad D, Ziabreva I, Lassmann H, Turnbull D . Mitochondrial defects in acute multiple sclerosis lesions . Brain . 131. Pt 7. 1722–35. 2008 . 18515320 . 10.1093/brain/awn105 . 2442422 .
  197. Smith SA, Farrell JA, Jones CK, Reich DS, Calabresi PA, van Zijl PC. Pulsed magnetization transfer imaging with body coil transmission at 3 Tesla: feasibility and application. Magn Reson Med. 56. 4. 866–75. October 2006. 16964602. 10.1002/mrm.21035. free.
  198. Goldberg-Zimring D, Mewes AU, Maddah M, Warfield SK. Diffusion tensor magnetic resonance imaging in multiple sclerosis. J Neuroimaging. 15. 4 Suppl. 68S–81S. 2005. 16385020. 10.1177/1051228405283363. 14196873.
  199. http://www.admin.ox.ac.uk/po/news/2006-07/sep/24.shtml New imaging technique allows doctors to 'see’ molecular activity
  200. West J, Aalto A, Tisell A, Leinhard OD, Landtblom AM, Smedby O, Lundberg P . 2014. Normal Appearing and Diffusely Abnormal White Matter in Patients with Multiple Sclerosis Assessed with Quantitative MR . PLOS ONE . 9. 4. e95161. 10.1371/journal.pone.0095161 . 24747946 . 3991609. 2014PLoSO...995161W. free.
  201. Tauhid S, Neema M, Healy BC, Weiner HL, Bakshi R . 2014. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis . Journal of the Neurological Sciences . 346. 1–2. 250–254. 10.1016/j.jns.2014.08.047 . 25220114. free.
  202. https://web.archive.org/web/20060213133848/http://brain.oxfordjournals.org/cgi/content/full/125/12/2784 Primary progressive multiple sclerosis
  203. Miguel Guerrero Fernández . es . Estudio longitudinal mediante imagen de resonancia magnética (RM) del efecto de la azatioprina (AZA) en pacientes con esclerosis múltiple remitente recurrente (EM-RR) refractarios al tratamiento con interferón beta-1b (IFN-1b) . Longitudinal study by magnetic resonance imaging (MRI) of the effect of azathioprine (AZA) in patients with relapsing remitting multiple sclerosis (RR-MS) refractory to treatment with interferon beta-1b (IFN-1b) . LIV Annual Meeting of the American Academy of Neurology. Denver (USA) . 2002 . 2017-05-31 . dead . https://web.archive.org/web/20071002111018/http://www.fedem.org/revista/n13/actualidad.html . 2007-10-02 .
  204. The Mystery of the Multiple Sclerosis Lesion, Frontiers Beyond the Decade of the Brain, Medscape http://doctor.medscape.com/viewarticle/433621
  205. Balk L, Tewarie P, Killestein J, Polman C, Uitdehaag B, Petzold A. Disease course heterogeneity and OCT in multiple sclerosis. Mult Scler. 2014 Jan 8
  206. Cepok S, Jacobsen M, Schock S . Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain. 124. Pt 11. 2169–76. November 2001. 11673319. 10.1093/brain/124.11.2169. etal . free.
  207. Cepok S, Jacobsen M, Schock S . Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis . Brain . 124 . Pt 11 . 2169–76 . November 2001 . 11673319 . 10.1093/brain/124.11.2169 . etal . free .
  208. Stich O, Perera S, Berger B, Jarius S, Wildemann B, Baumgartner A, Rauer S . Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis . Journal of the Neurological Sciences . March 2016 . 10.1016/j.jns.2016.03.004 . 27084211 . 364 . 29–32. 29204735 .
  209. 10.1056/NEJMoa1100648 . 22150037 . Inflammatory Cortical Demyelination in Early Multiple Sclerosis . New England Journal of Medicine . 365 . 23 . 2188–97 . 2011 . Lucchinetti . Claudia F . Popescu . Bogdan F.G . Bunyan . Reem F . Moll . Natalia M . Roemer . Shanu F . Lassmann . Hans . Brück . Wolfgang . Parisi . Joseph E . Scheithauer . Bernd W . Giannini . Caterina . Weigand . Stephen D . Mandrekar . Jay . Ransohoff . Richard M . 3282172 .
  210. Fernández O, Fernández V, Mayorga C . HLA class II and response to interferon-beta in multiple sclerosis . Acta Neurol Scand . 112 . 6 . 391–4 . December 2005 . 16281922 . 10.1111/j.1600-0404.2005.00415.x . 10642034 . etal .
  211. van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL . Pharmacogenomics of Interferon-β Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients . PLOS ONE . 3 . 4 . e1927 . 2008 . 18382694 . 2271130 . 10.1371/journal.pone.0001927 . Lassmann . Hans . 1 . 2008PLoSO...3.1927V . free .
  212. Wiesemann E, Deb M, Hemmer B, Radeke HH, Windhagen A . Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis . Clinical Immunology . 128. 3. 306–13. 2008 . 18539537 . 10.1016/j.clim.2008.04.007.
  213. Axtell RC, etal . T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis . Nat Med . 16. 4. 406–12. 10.1038/nm.2110 . 20348925 . 3042885 . April 2010.
  214. Carrieri PB, Ladogana P, Di Spigna G, etal . Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders . Immunopharmacol Immunotoxicol . 30 . 4 . 1–9 . 2008 . 18686100 . 10.1080/08923970802302753. 20663030 .
  215. http://www.medicalnewstoday.com/medicalnews.php?newsid=29100 Patients' Multiple Sclerosis Lesion Type Dictates Effective Treatment
  216. Bitsch A, Brück W. Differentiation of multiple sclerosis subtypes: implications for treatment. CNS Drugs. 16. 6. 405–18. 2002. 12027786. 10.2165/00023210-200216060-00004. 26020045.
  217. Debouverie M, Moreau T, Lebrun C, Heinzlef O, Brudon F, Msihid J . A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate . Eur J Neurol . 14 . 11 . 1266–74 . November 2007 . 17956447 . 10.1111/j.1468-1331.2007.01964.x . 28090063 .
  218. Carrá A, Onaha P, Luetic G . Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina . Eur J Neurol . 15 . 4 . 386–93 . 2008 . 18353125 . 10.1111/j.1468-1331.2008.02071.x . 15274281 . etal .
  219. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E . Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis . Multiple Sclerosis . October 2008 . 18922831 . 10.1177/1352458508096687 . 15 . 1 . 50–8 . 10488624 .
  220. Byun E, Caillier SJ, Montalban X . Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol. 65. 3. 337–44. March 2008. 18195134. 10.1001/archneurol.2008.47. etal .
  221. Vandenbroeck K, Matute C . Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen . Pharmacogenomics . 9 . 5 . 639–45 . May 2008 . 18466107 . 10.2217/14622416.9.5.639 .
  222. 10.1016/j.neurol.2013.02.010 . 24139243 . Formes cavitaires de sclérose en plaques : étude multicentrique sur vingt patients . Revue Neurologique . 169 . 12 . 965–9 . 2013 . Corlobé . A . Renard . D . Goizet . C . Berger . E . Rumbach . L . Robinson . A . Dupuy . D . Touzé . E . Zéphir . H . Vermersch . P . Brochet . B . Edan . G . Deburghgraeve . V . Créange . A . Castelnovo . G . Cohen . M . Lebrun-Frenay . C . Boespflug-Tanguy . O . Labauge . P .
  223. Berger, etal . Oct 2014 . Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics . J Neuroimmunol . 277 . 1–2. 145–152 . 10.1016/j.jneuroim.2014.10.001 . 25454729. 38618004 .
  224. 10.1016/j.jns.2014.11.019 . 25480016 . The co-occurrence of multiple sclerosis and type 1 diabetes: Shared aetiologic features and clinical implication for MS aetiology . Journal of the Neurological Sciences . 348 . 1–2 . 126–31 . 2015 . Tettey . Prudence . Simpson . Steve . Taylor . Bruce V . Van Der Mei . Ingrid A.F . 1973768 .
  225. Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, Nicholas R, Roncaroli F, Reynolds R . Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis . Brain . 135. Pt 10. 2925–37. 10.1093/brain/aws189 . 22907116 . October 2012. free.
  226. Paling D, Solanky BS, Riemer F, Tozer DJ, Wheeler-Kingshott CA, Kapoor R, Golay X, Miller DH . Sodium accumulation is associated with disability and a progressive course in multiple sclerosis . Brain . 136. Pt 7. 2305–17. 10.1093/brain/awt149 . 23801742 . Jul 2013. free.
  227. Vrenken H. . 2010 . Diffusely Abnormal White Matter in Progressive Multiple Sclerosis: In Vivo Quantitative MR Imaging Characterization and Comparison between Disease Types . American Journal of Neuroradiology. 31 . 3. 541–548 . 10.3174/ajnr.A1839 . 19850760. 7963986 . etal. free .
  228. Lassmann H . Nov 2009 . Clinical and pathological topics of multiple sclerosis . Rinsho Shinkeigaku . 49 . 11. 715–8 . 20030193 . 10.5692/clinicalneurol.49.715. free .
  229. Emanuele D’Amico . Francesco Patti . Aurora Zanghì . Mario Zappia. A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. Int. J. Mol. Sci.. October 2016. 10.3390/ijms17101725 . 27763513 . 5085756 . 17 . 10 . 1725. free .
  230. 10.3174/ajnr.A4690 . 26965463 . White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis . American Journal of Neuroradiology. 37 . 6 . 1030–7 . 2016 . Wiebenga . O.T . Schoonheim . M.M . Hulst . H.E . Nagtegaal . G.J.A . Strijbis . E.M.M . Steenwijk . M.D . Polman . C.H . Pouwels . P.J.W . Barkhof . F . Geurts . J.J.G . 7963536 . free .
  231. Michel L, etal . 2015 . B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation . Front Immunol . 6 . 636 . 10.3389/fimmu.2015.00636. 26732544 . 4689808 . free .
  232. Magliozzi R, etal . 2006. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology . Brain . 130. 4. 1089–1104. 10.1093/brain/awm038. 17438020. free.
  233. Serafini B, etal . 2004. Detection of Ectopic B-cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis . Brain Pathology. 14. 2. 164–174. 10.1111/j.1750-3639.2004.tb00049.x. 15193029. 24320315. 8095922.
  234. Frisullo G, Nociti V, Iorio R . The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis . J Neuroimmunol . 205 . 1–2 . 126–34 . December 2008. 18926576 . 10.1016/j.jneuroim.2008.09.003 . 27303451 . etal .
  235. 10.1093/brain/awp342 . Acute disseminated encephalomyelitis and multiple sclerosis . 2010 . Lassmann H . Brain . 133 . 2 . 317–319 . 20129937. free .
  236. Lebrun C, Bensa C, Debouverie M . Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile . Journal of Neurology, Neurosurgery & Psychiatry. 79 . 2 . 195–198 . 2008 . 18202208 . 10.1136/jnnp.2006.108274 . 11750372 . etal .
  237. Nakamura M, Morris M, Cerghet M, Schultz L, Elias S . Fall 2014 . Longitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple Sclerosis . Int J MS Care . 16 . 3. 111–5 . 10.7224/1537-2073.2013-016 . 25337052 . 4204370.
  238. Hakiki B, Goretti B, Portaccio E, Zipoli V, Amato MP . Subclinical MS: follow-up of four cases . European Journal of Neurology. 15. 8. 858–61. 2008 . 18507677 . 10.1111/j.1468-1331.2008.02155.x . 27212599 .
  239. Engell T . A clinical patho-anatomical study of clinically silent multiple sclerosis . Acta Neurol Scand . 79 . 5 . 428–30 . May 1989 . 2741673 . 10.1111/j.1600-0404.1989.tb03811.x . 21581253 . free .
  240. 9599334 . 4 . 2 . Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions . April 1998 . Mews I, Bergmann M, Bunkowski S, Gullotta F, Brück W . Mult Scler . 55–62 . 10.1177/135245859800400203. 36657898 .
  241. Siva A . Dec 2013 . Asymptomatic MS. . Clin Neurol Neurosurg . 115 . Suppl 1. S1–5 . 10.1016/j.clineuro.2013.09.012 . 24321147 . 29282376 .
  242. Giorgio A . Nov 2011 . Cortical lesions in radiologically isolated syndrome . Neurology . 77 . 21. 1896–9 . 10.1212/WNL.0b013e318238ee9b . 22076541 . 22178831 . etal.
  243. De Stefano N . Apr 2011 . Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis . PLOS ONE . 6 . 4. e19452 . 10.1371/journal.pone.0019452 . etal. 2011PLoSO...619452D . 21559385 . 3084867. free .
  244. Granberg T . Mar 2013 . Radiologically isolated syndrome--incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review . Mult Scler . 19 . 3. 271–80 . 10.1177/1352458512451943 . 22760099 . 24307387 . etal.
  245. Stromillo ML . Jun 2013 . Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome . Neurology . 80 . 23. 2090–4 . 10.1212/WNL.0b013e318295d707 . 23635962 . 36065815 . etal.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pathology of multiple sclerosis".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.